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Abstract 
Chronic kidney disease (CKD) is a significant public health issue. The 
uraemic milieu is associated with profound alterations in body 
composition and function. Therapeutic interventions to preserve renal 
function and to provide adequate homeostasis to improve outcomes in 
all stages of chronic kidney disease may promote other unwanted 
functional adversities which with careful attention to individualised 
treatment may be modifiable. 
The aim of this thesis is to clearly document these disorders of body 
composition and function and investigate whether commonly practiced 
interventions can indeed have additional deleterious impact. Our work 
involved subjects with different levels of CKD and included: 
• Antihypertensive therapy and falls in older persons with CKD 3/4. 
• Assessment of dynamic bone function in ERF subjects treated 
with haemodialysis and consequences of phosphate binder 
medication. 
• Distinguishing the dominant cardiac functional abnormalities in 
ERF subjects treated with haemodialysis and determination of the 
effects of haemodialysis on camitine depletion and its functional 
consequences (skeletal and myocardial). 
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Key results included: 
• Antihypertensive therapy in older subjects with CKD was 
associated with a reduction in muscle mass over time and 
reduced overall function but no significant falls risk was noted. 
• Commonly utilised measurements to determine bone turnover in 
ERF subjects treated with haemodialysis do not appear to 
correlate with dynamic collagen formation rates. 
• Dobutamine-atropine stress with non-invasive assessment of 
cardiac parameters can be used to identify the dominant 
functional abnormalities that predispose to intradialytic 
hypotension in ERF subjects. 
• Skeletal muscle total carnitine decreases over the first 12 months 
of dialysis. Change in muscle total carnitine correlated weakly 
with exercise capacity. Carnitine replacement did not confer any 
measurable cardiovascular benefit over the first 12 months of 
dialysis. 
Body composition is highly variable over time in CKD. This is seen both 
in subjects receiving haemodialysis and in pre-dialysis patients. The 
interplay of these common alterations with the effects of treatments is 
potentially underestimated but should always be considered in the 
individualisation of patient care. 
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1 INTRODUCTION 
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INTRODUCTION 
1.1 Chronic Kidney Disease 
Chronic kidney disease (CKD) is a global public health issue. It is 
defined as the presence of markers of kidney damage for ~ ~ 3 months, 
characterised by structural or functional abnormalities of the kidney, with 
or without a decrease in glomerular filtration rate (GFR). It is manifest by 
either pathological abnormalities in the composition of blood or urine, or 
abnormalities in imaging tests. It can also be defined as the presence of 
a GFR<60mVminl1.73m2 for ~ ~ 3 months, with or without other signs of 
kidney damage (1) .. 
The current international classification system of the five different stages 
of CKD, developed by the US National Kidney Foundation in their 
'Kidney Disease Outcomes Quality Initiative (K/DOQI) is shown below. 
I Stage 
I 
, Description ! GFR . 
2 
I 
I (mVminl1.73m ) 
I 
1 Kidney damage with normal or high GFR ~ 9 0 0
I 
2 Kidney damage and mild decrease in GFR 60 to 89 
I 
3 Moderate decrease in GFR I 30 to 59 
4 Severe decrease in GFR 15 to 29 
5 Kidney Failure/Established Renal Failure (ERF) <15 or on dialysis 
Table1. ClassifICation of CKD 
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A survey of blood samples from patients in the South East of England 
taken in 2000-2001 found the prevalence of diagnosed CKD to be 5554 
per million population (2). Only a minority of subjects with CKD 1 and 2 
will go on to develop Established Renal Failure (CKD 5). Of those with 
CKD 4 only one third will survive to progress to CKD 5 and potentially 
require dialysis. The number of patients being accepted onto renal 
replacement programmes is however increaSing. Some models suggest 
acceptance rates may not reach steady states for another 25 years (3). 
Patients with CKD 5 consume a disproportionate share of health care 
resources. In the UK, renal replacement therapies account for over 2% 
of the total NHS budget. Despite the resources committed and the 
substantial improvements in the qualities of dialysis therapies, these 
patients still have significant mortality and morbidity. Survival 
probabilities for dialysis patients at 1, 2, 5 and 10 years are 
approximately 80%,67%.40% and 18% respectively (4). Timely. cost-
effective intervention, to address known risk factors for progression in 
the earlier stages of CKD is therefore paramount and has been the focus 
of the development of national treatment and referral guidance to 
specialist services over recent years. 
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1.2 Body composition in chronic kidney disease 
The uraemic milieu is associated with alterations in body composition 
and function that result in a wide ranging set of clinical consequences. 
These sequelae tend to be more significant with an increasing degree of 
renal impairment. 
1.2.1 Muscle 
CKD is associated with both muscle wasting and reduced functional 
capacity (5, 6). The aetiology of these has not been fully elucidated. The 
potential mechanisms involved are multifaceted and complex. These 
include decreased physical activity, alterations in substrate delivery and 
muscle perfUSion, poor nutritional status and the presence of a catabolic 
state, mediated by factors such as metabolic acidosis, insulin resistance 
and prO-inflammatory cytokines. 
In terms of structure, studies of patients with CKD 5 have demonstrated 
significant atrophy of myofibres, across all fibre types (particularly type II 
fibres), in both locomotor (7) and non-locomotor muscles (8). Although 
disuse atrophy in these subjects is probably a factor this evidence 
supports the contributory role of direct effects of uraemia. 
Reduced muscle protein synthesis has been demonstrated in subjects 
with CKD as compared to non-uraemic controls (9). No data are 
available on whether or not this is proportional to the severity of uraemia. 
Metabolic acidosis is known to cause accelerated protein degradation in 
children (10), adults (11) and subjects with CKD (12, 13). Metabolic 
acidosis is an inevitable consequence of renal failure (14). The 
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correction of metabolic acidosis has been shown in clinical trials to 
decrease protein breakdown. highlighting why maintenance of a normal 
serum bicarbonate level should be part of routine clinical care. The 
mechanism by which metabolic acidosis causes muscle wasting is by 
activation of the Ubiquitin-proteasome system and caspase-3 (15.16). In 
addition. acidosis modifies hormonal responses, contributing to insulin 
resistance and increased glucocorticoid production. Both of these 
processes are involved in the activation of protein degradation (17. 18). 
CKD is associated with chronic low grade inflammation. Subjects with 
CKD exhibit elevated circulating levels of interleukin-6 (IL-6) (19. 20). IL-
6 can negatively affect insulin and insulin-like-growth-factor I (IGFI) 
receptor signalling promoting catabolism and muscle atrophy. The pro-
inflammatory cytokine Tumor necrosis factor-a (TNF-a). is also 
commonly elevated in CKD patients. Activation of TNF-a receptors can 
potentially promote muscle protein wasting by a number of actions. TNF-
a signalling can activate caspase-3 a factor involved in breakdown of 
myofibrillar proteins (15). TNF-a can also stimulate the activation of the 
transcription factor NF-kB. thereby increasing tranSCription of 
components of the ubiquitin system (21). 
Activation of the renin-angiotensin system plays a major role in the 
progression of renal disease (22). It has also been shown to promote 
catabolism and skeletal muscle atrophy (23) through its actions on IGFI. 
This phenomenon may in part be responsible for the reduction in muscle 
mass associated with congestive cardiac failure in which the renin-
angiotensin system is also commonly activated. 
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There are a myriad of somatic systems that can regulate the 
anabolic/catabolic balance in skeletal muscle. Renal impairment, its 
consequences and in some instances its associated therapeutic 
interventions, can interact with and alter many of these systems critical 
for the maintenance of muscle mass (24). 
1.2.2 Consequences of Dialysis on muscle 
Dialysis processes in their own right can also directly contribute to 
muscle wasting and dysfunction. There is compelling evidence that 
haemodialysis and the associated depletion of Circulating amino acids 
contribute to net skeletal muscle protein loss (25). Elevated levels of 
Circulating prO-inflammatory cytokines such as IL-6 may increase further 
in response to haemodialysis (26). 
In prevalent ERF patients treated with haemodialysis, the characteristics 
of cardiovascular disease and progressive impairment of exercise 
capacity have been linked with reduced serum L-camitine and 
secondary depletion of skeletal muscle camitine. Camitine is a naturally 
occurring compound found in meat and dairy products. In health it is also 
produced in the liver and kidney. The majority is stored within skeletal 
and cardiac muscle where it has a major role in translocation of fatty 
acids into mitochondria for I3-oxidation and eventually ATP production. 
Two main mechanisms account for camitine defiCiency in haemodialysis 
patients. Firstly, the failing kidneys are unable to synthesise camitine 
and the body must rely on dietary sources to maintain carnitine stores. 
The second and more severe is that during dialysis, camitine is readily 
filtered and not replaced, causing a rapid fall in plasma carnitine levels. 
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A recovery in this faU in plasma camitine is observed several hours post 
haemodialysis due to a leaching of carnitine from skeletal and perhaps 
cardiac muscle. This results in a gradual deficiency in muscle stores 
over time. Improvements in the incidence of skeletal muscle carnitine 
levels and function have been reported in patients receiving L-carnitine 
supplementation. Interestingly, relating to myocardial function, L-
carnitine supplementation has also been shown to ameliorate cardiac 
arrhythmias (27) and left ventricular ejection fraction (28) in prevalent 
haemodialysis patients. More importantly there is also some published 
evidence that supplementation is associated with a significant reduction 
in the occurrence of intradialytic hypotension (29, 30) offering a potential 
solution to this driver of long-term myocardial damage within the 
haemodialysis population. 
Published investigations have been limited by a lack of any data on the 
natural history of carnitine depletion, by size and scope of techniques 
applied (particularly with respect to myocardial function) and paucity of 
data on intramuscular camitine levels. 
1.2.3 Fat 
There is considerably less literature regarding changes in fat mass and 
function in the uraemic setting when compared to the evidence base 
relating to muscle. In patients with ERF treated by haemodialysis fat 
mass correlates with increasing age (31). Low baseline percentage body 
fat and fat loss over time have been independently associated with 
increased mortality (32). 
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Much of the available data regarding body fat in CKD was generated 
through work on the Malnutrition-Inflammation-Atherosclerosis (MIA) 
complex. These factors often coexist in both pre-dialysis and dialysis 
dependent subjects with CKD (33, 34, 35). The presence of these 
factors often predicts poor outcome (33, 34, 36). It is becoming 
increasingly evident that far from being an inert energy storage facility, 
fat contributes to the elevated levels of chronic inflammation prevalent in 
the CKD population via secretion of adipokines (including leptin and 
adiponectin) and cytokines (TNFa and IL-6) (37). 
1.2.4 Bone 
Although often considered an inert organ, in health, the skeleton is 
metabolically active and is constantly remodelling. Its metabolic 
functions are chiefly as a store for calCium, phosphate and carbonate. 
Structurally it is critical for locomotion, respiration and protection of 
intemal organs. 
Normal bone turnover is preserved by continued remodelling. Old or 
damaged bone is removed by osteoclastic mediated resorption. This is 
followed by new bone production mediated by osteoblasts. This coupled 
bone formation and resorption occurs in discrete compartmentalised 
units termed Bone structural units (BSU). The total number of BSUs on 
the bone surface as well as the activity of the osteoblasts and 
osteoclasts within each, dictate the rate of bone tumover. 
The interaction between osteoclasts and osteoblasts is governed by the 
receptor activator NFkB ligand (RANK-L). This is a transmembrane 
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protein that is expressed predominantly on the surface of cells from the 
osteoblast lineage. It interacts with a receptor on osteoclast precursors 
called RANK. This RANK-LIRANK interaction causes activation, 
migration and differentiation of the osteoclast lineage to begin the 
process of resorption. Osteoprotegerin (OPG) is a decoy receptor, also 
expressed by osteoblasts. It blocks the interaction of RANK-LlRANK, 
thereby inhibiting osteoclast differentiation and activity (38). This 
RANKLlRANKIOPG relationship is mediated by various cytokines and 
systemic factors such as IL-6, IL-1, TNFa, thyroid hormone, PTH and 
Vitamin 0, thus impacting on bone metabolism and remodelling (39). 
With progressive renal dysfunction CKO-mineral bone disorder (CKO-
MBO) ensues. This is almost universal when patients have ERF and 
tends to progress as the state of renal failure is prolonged with dialysis 
therapies. This systemic disorder of mineral and bone metabolism is 
manifest by a combination of: 
1) Abnormalities of calcium, phosphorus, PTH or vitamin 0 metabolism. 
2) Abnormalities in bone turnover, mineralization, volume, linear growth or 
strength. 
3) Vascular or other soft tissue calcification. 
Renal osteodystrophy is an alteration of bone morphology in patients 
with CKO. It is one measure of the skeletal component of CKO-MBO that 
is quantifiable by histomorphometry of bone biopsy (40). It consists of a 
spectrum of disorders. Patients often have evidence of more than one 
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specific disorder. For the purpose of simplification it can be divided into 
four main categories: 
1) Osteitis Fibrosa Cystica (OFC) 
2) Osteomalacia 
3) Adynamic Bone Disease 
4) Mixed Osteodystrophy 
The exact pathophysiological processes involved in OFC are not yet fully 
elucidated. However, there are several key mechanisms which play a 
role. With deteriorating GFR there is an associated reduction in the 
filtered phosphate load leading to phosphate retention. This in tum 
results in reduced calcium levels causing an increase in parathyroid 
hormone (PTH). This is mediated via the calcium sensing receptor which 
is highly expressed in the parathyroid glands, permitting variations in the 
serum calcium concentration to be sensed by the parathyroid glands 
leading to the desired changes in PTH secretion. There is also an 
increasing failure of the kidney to synthesise 1.25 Dihydroxyvitamin 03 
(calcitriol). In part this may be due to a reduction in functioning renal 
mass. Phosphate retention may adversely affect calcitriol production by 
influencing the regulation of the enzyme responsible for its production. 
In addition, experimental studies suggest that the conversion of calcidiol 
to calcitriol can be diminished by substances retained in renal failure, 
including uraemic toxins and uric acid (41). These may also contribute to 
decreased responsiveness to calcitriol by modulating calcitriol receptor 
synthesis and receptor function. Decreased calcitriol activity leads to 
reduced intestinal calcium absorption, hypocalcaemia and consequently 
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an increase in PTH. With reduced levels of calcitriol there is also a 
reduction in the normal inhibitory action it would have on the parathyroid 
glands to limit the production of PTH. The subsequent action of PTH on 
the skeleton causes a release of calcium (and phosphate), thereby 
restoring plasma calcium levels towards normal. Initially the inhibitory 
effect of PTH on proximal phosphate reabsorption can lead to a 
reduction in the fraction of filtered phosphate reabsorbed from the 
normal proportion of 80-95% to 15%. However, once this limit is 
attained, phosphate reabsorption cannot be lowered any further. Another 
factor that appears to contribute to the genesis of secondary 
hyperparathyroidism in CKD is the development of skeletal resistance to 
the calcaemic action of PTH. This resistance appears to be due in part 
to down regulation of PTH receptors, induced by elevated circulating 
levels of PTH. Calcitriol deficiency and hyperphosphataemia are also 
thought to playa role. Continued PTH-induced release of phosphate 
from bone exacerbates hyperphosphataemia, results in bone disease 
and contributes toward metastatic calcification. The characteristic 
histological findings at bone biopsy in such patients are of increased 
number and activity of osteoblasts, expansion of osteoid surfaces and 
numerous osteoclasts and resorptive surfaces. Distinct tetracycline 
labels will indicate accelerated bone formation in the absence of a 
mineralisation defect. 
Osteomalacia is characterised by a reduction in bone turnover, the 
appearance of osteoclasts and osteoblasts and an increase in the 
amount of unmineralised bone. It can occur as a result of Vitamin D 
26 
deficiency. A large number of cases over previous decades now appear 
to have resulted secondary to aluminium intoxication from treatment with 
aluminium containing phosphate binder medication, used to prevent 
hyperphosphataemia in patients with CKD. The use of these 
medications has now fallen dramatically as has the incidence of this 
condition in CKD patients. 
In adynamic bone disease, bone turnover is markedly reduced. It is 
characterised histologica"y by thin osteoid seams that display no active 
mineralisation, inactive appearing osteob lasts , and decreases in 
osteoclast number and bone resorptive surfaces. It is the most common 
form of bone disease found in those patients receiving haemodialysis. 
Several risk factors have been identified: increasing age, diabetes and 
increased calcium load. The principle mechanism is thought to be 
excess suppression of hyperparathyroidism with phosphate binding 
medication and Vitamin D analogues. Adynamic bone (associated with a 
low PTH level) with reduced functional status impairs the ability of the 
skeleton to buffer exogenous calcium load and increases the risk of 
metastatic calcification. A study of haemodialysis patients in 2004 
undergoing assessment of vascular calcification by ultrasound and bone 
formation rate by histomorphometric biopsy demonstrated that those 
with lowest bone formation rates and decreased osteoblastic surface 
had the greatest degree of vascular calcification (42). 
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1.2.5 Therapeutic stratergies in CKD-MBD 
Hyperphosphataemia 
The KlDOQI clinical practice guidelines for bone metabolism and 
disease in CKD (43) recommend target serum phosphate concentrations 
of: 
• 0.87-1.49 mmoVL in patients with a GFR in the range 15-59 
mUmin/1.73m2 
• 1.13-1.78 mmoVL in patients with a GFR s15 mUmin/1.73m2 
A large percentage (60-70%) of dietary phosphate is absorbed by the 
gut and in health would normally be excreted by the kidneys. There are 
two general modalities used to attempt to reverse the 
hyperphosphataemia of CKD. These are restriction of dietary phosphate 
intake and administration· of agents that bind ingested phosphate in the 
gut and prevent its absorption. 
Phosphate restriction is accomplished by limiting protein intake. This 
may also have some benefits in earlier phases of CKD as there is 
evidence to suggest that a low protein diet may reduce their rate of 
progression of renal impairment. Such approaches need careful 
monitoring however. Malnutrition is a relatively common finding in 
patients with advancing renal failure. The aetiology of this is complex but 
includes reduced appetite as a consequence of increasing uraemia and 
altered metabolism. A large proportion of dialysed patients have either 
overt or borderline malnutrition. In a study of nearly 54,000 maintenance 
haemodialysis patients, low daily protein intake or decrease in its 
magnitude over time has been shown to be associated with an 
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increased risk of death (44). Low albumin and other markers of 
malnutrition, independent of markers of chronic inflammation, are also 
associated with increased rates of vascular calcification (45). 
Ideally, as kidney function deteriorates the net quantity of phosphate 
absorbed from the GI tract should be proportionally reduced to match 
the decrease in kidney function (46). Given the limitations to dietary 
restriction outlined above, oral phosphate binding medications are 
commonly utilised to minimise phosphate absorption. 
Currently oral binders based on calcium (predominantly carbonate or 
acetate) are the most widely used therapeutic options to cope with 
hyperphosphataemia in CKD. Calcium is limited by toxicity in a 
significant proportion of patients (47). 
Sevelamer is a mineral free phosphate binder. This drug is a cationic 
polymer that binds phosphate through ion exchange. It has been shown 
to be effective in both short and long term studies (48, 49). The 
reduction in elemental calcium load seen with the use of this agent may 
be important in reducing the effect of cardiovascular and metastatic 
calcification (50). Studies in haemodialysis patients have shown that the 
management of hyperphosphataemia in these subjects with calcium 
salts is associated with a significantly greater progression of coronary 
artery calcification score than those treated with sevelamer (51, 52). In 
subjects new to haemodialysis baseline coronary artery calcification 
score is a significant predictor of all cause mortality. Treatment with 
sevelamer was associated with a significant survival benefit as 
compared to the use of calcium salts (53). A study using a murine 
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model of CKD-induced vascular calcification has suggested that 
Sevelamer Carbonate may actually be capable of a reduction in 
established vascular calcification, reverse CKD-induced trabecular 
osteopenia and increase bone formation rates (54). 
Lanthanum carbonate has significant phosphate binding properties. 
Multiple studies have shown it to be effective at lowering phosphate 
levels. In a large multi-centre European study its effect at lowering 
phosphate was shown to be comparable to that of calcium carbonate but 
the incidence of hypercalcaemia was markedly lower, 0.4 versus 20.2% 
(55). In addition, lanthanum carbonate has also been shown to improve 
the histomorphometric bone biopsy findings when compared to calcium 
carbonate and may therefore be useful as a means to normalise bone 
turnover in dialysis patients (56). No significant clinical adverse effects 
have yet been reported with lanthanum. 
Hyperparathyroidism 
The medical management of secondary hyperparathyroidism in patients 
with CKD principally involves control of hyperphosphataemia and 
suppression of PTH production using active vitamin 0 analogues and 
calcimimetics. 
The contribution of calcitriol defiCiency to the development of secondary 
hyperparathyroidism constitutes the rationale for the use of active 
vitamin 0 analogues. The ability of all available vitamin 0 analogues to 
induce hyperphosphataemia and hypercalcaemia and promote vascular 
calcification in high doses, obviously impacts on their usefulness. Up to 
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one half of patients with severe hyperparathyroidism show little or no 
decline in plasma PTH levels with calcitriol. Limiting factors include 
altered calcium sensitivity of parathyroid cells, larger functioning 
parathyroid mass and ensuing hypercalcaemia and 
hyperphosphataemia. 
Calcimimetic agents, which increase the sensitivity of the calcium 
sensing receptor in the parathyroid glands to calcium, are an additional 
option for reducing PTH levels in more resistant patients. Cinacalcet is 
currently the only available calcimimetic. It has been shown in large 
efficacy studies to improve the likelihood of achieving KlOOQI defined 
clinical targets for patients with CKO related bone disease (57). 
1.3 Cardiovascular risk and myocardial dysfunction 
The leading cause of mortality and morbidity in subjects with CKO is 
cardiovascular disease (CVO). Indeed the risk of death due to CVO is 
much higher than the risk of ultimately requiring renal replacement 
therapy (58, 59). Subjects with CKO have been shown to have a higher 
prevalence and incidence of ischemic heart disease (IHO) and heart 
failure (60, 61). They are also at higher risk of death after an acute 
myocardial infarction (62, 63). This is very clearly shown in several 
epidemiological studies researching morbidity and mortality in patients 
with CKD. In the Cardiovascular Health Study which was carried out in a 
population over 65 years of age, 26% of subjects with CKD had IHO and 
55% had hypertension. This was in contrast to patients without CKD, 
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3% had IHD and 36% were hypertensive. Furthermore, it was shown 
that CKD subjects had a CVD event rate of 102 per 1000 patient year in 
contrast to subjects without CKD (event rate of only 44 per 1000 patient 
year (64). In a cross sectional study of 175 patients, 27% of patients with 
creatinine clearance (erCl) >50 mUmin and 31% of patients with CrCl 
25-49 mUmin had left ventricular hypertrophy (LVH). The prevalence of 
LVH increased to 45% when CrCl dropped below 25mUmin (65). This is 
in contrast to the 20% prevalence of L VH in an aged-matched general 
population (66). 
Cardiovascular risk is clearly present in the early stages of CKD. In part 
this is attributable to the presence of more traditional risk factors such as 
hypertension and diabetes. However, there is an increasing body of 
evidence to show that CKD alone is an independent risk factor for 
cardiovascular disease. 
Vascular calcification is recognised as a common and functionally 
important finding in patients with CKD. Patients receiving haemodialysis 
who have vascular calcification have a 40 fold increase in their relative 
risk of cardiovascular death compared to those who do not (67). 
Vascular calcification is rapidly progressive in both the majority of 
patients receiving dialysis and those with CKD stage 4 (51, 45). 
Disorders of bone and mineral metabolism have been shown to be 
associated with cardiovascular mortality. Progressive calcification of the 
arterial tree is one mechanism by which this occurs. Vascular 
calcification or ossification, as it might be more accurately termed, is an 
active process with phenotypic transformation of vascular smooth 
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muscle cells to an osteoblastic phenotype. This results in active 
production and mineralisation of bony matrix. This process is modulated 
by many factors. These include phosphorus, vitamin 0 and Circulating 
modulators of calcification. Fetuin and matrix gla protein have been 
reported to be involved in this ossification (68). Elevated serum levels of 
osteoprotegerin have been described as being associated with both 
prevalent and progressive aortic calcification in haemodialysis patients 
(69). Vitamin 0 defiCiency, a common finding in patients with ERF, has 
been shown to be independently associated with abnormal conduit and 
capacitive functions of large arteries in stable haemodialysis patients 
(70). 
Patients with ERF are subject to an epidemic of cardiovascular disease 
with massively elevated rates of cardiovascular morbidity and mortality 
(71). Amongst the ERF population treated with dialysis, CVD accounts 
for up to 45% of deaths (72). Within the haemodialysis population, the 
prevalence of factors such as LVH, coronary artery disease and vascular 
calcification amongst others, predispose to reduced coronary flow 
reserve, resulting in myocardial hypoperfusion. This can lead to 
segmental ischaemia, inducing segmental left ventricular dysfunction 
(73), a process known as myocardial stunning (74). This recurrent injury 
is critically dependant on intradialytic hypotension (IDH) and 
ultrafiltration rate. IDH has been reported in about 30% of dialysis 
sessions (75, 76, 77). It is associated with high rates of morbidity and 
mortality (78). The pathophysiology of IDH is multifactorial but involves 
inadequate compensatory mechanisms to hypovolaemia induced by 
33 
ultrafiltration. These include a decrease in venous capacitance, increase 
in total peripheral resistance and increased cardiac output (75). Failure 
of any of these mechanisms predisposes patients to IDH. The resultant 
myocardial stunning is cumulative and leads to irreversible left 
ventricular dysfunction in ischaemic heart disease. This pattern of injury 
is common in both adults and children receiving haemodialysis and is 
associated with a marked increase in mortality. Modifications in the 
standard dialysis prescription to improve the haemodynamic response 
have been shown, in the short-term, to ameliorate this cardiac injury. 
1.4 Hypertension and blood pressure guidelines 
Given the burden of cardiovascular risk within the CKD population, 
aggressive treatment to reduce risk factors is an essential tenet in the 
management of CKD at all stages. Effective management of 
hypertension is a cornerstone of therapy. 
The treatment of hypertension provides· benefit by both slowing the rate 
of progression of CKD and reducing cardiovascular risk. The optimal 
level of blood pressure control is less clear. The Modification of Diet in 
Renal Disease (MORO) Study Group demonstrated that the level of 
proteinuria at baseline significantly modulated the effect of blood 
pressure lowering such that a lower target blood pressure of 
s125175mmHg compared to S140/90mmHg was associated with a 
slower rate of GFR decline among patients with >1g/day proteinuria (79). 
Subsequent data analysis from this study demonstrated significant 
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correlation between rate of GFR decline and achieved blood pressure 
prompting suggested target blood pressure levels of <130/S0mmHg for 
subjects with <1g/day of proteinuria and <125175mmHg for those with 
>1g1day of proteinuria (SO). More recently, the ESCAPE trial group 
published results from their study of intensified blood pressure control 
among children with CKD. This demonstrated that randomisation to a 
lower target blood pressure was associated with a Significantly reduced 
risk of reaching ERF or doubling of serum creatinine (S1). A meta-
analysis of 11 randomised control trials comparing the efficacy of 
antihypertensive regimens with or without ACE inhibitors for patients 
with predominantly non-diabetic.renal disease, including data from 1S60 
subjects, reported the lowest risk for kidney disease progression to be at 
levels of systoliC blood pressure between 110 and 129mmHg with urine 
protein excretion >1 g/day. A potential increase in risk of progression was 
noted at systOliC blood pressure of <11OmmHg (S2). The results of the 
Irbesartan Diabetic Nephropathy trial again demonstrated that 
progressive lowering of systolic blood pressure to 120mmHg was 
associated with improved patient and renal survival. However, below this 
threshold, all-cause mortality increased (S3). The ACCORD Study 
reported no additional benefit with respect to cardiovascular end-points 
among patients with type II diabetes randomised to strict blood pressure 
control «12OmmHg systolic) or standard control «140mmHg) but 
increased treatment related adverse events and demonstrated a greater 
decline in GFR in the lower target blood pressure group (84). Similarly, 
secondary analysis of data from the ONTARGET trial demonstrated a 
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higher cardiovascular mortality in subjects who achieved a systolic blood 
pressure of <120mmHg than those achieving 120-129mmHg (85). Thus 
there are potential dangers with excessive blood pressure lowering and 
caution must be exercised particularly in subjects with evidence of 
autonomic neuropathy or postural hypotension. Autonomic dysfunction is 
relatively common in subjects receiving dialysis and those with 
significant CKD. Short term regulation of blood pressure is largely 
controlled by appropriate autonomic activity through the baroreflex arc. 
Activity of this system or baroreflex sensitivity (BRS) is well recognised 
as a composite marker of the overall integrity of the autonomic nervous 
system (86). Alterations in BRS are associated with an increased 
incidence of cardiac arrythmias, falls propensity, intradialytic 
haemodynamic instability, cardiovascular events and all cause mortality 
(87, 88, 89). 
CKD is prevalent in older people. Greater than 25% of individuals aged 
above 70 years have CKD 3 or 4. Only a small proportion of these will 
ever progress to CKD 5. Treatment is directed towards reducing 
cardiovascular risk factors, in particular hypertension. Advancing age is 
associated with changes in body composition. These include hydration 
status, alteration in lean body mass, reduction in muscle function and 
skeletal changes. As already discussed, these are also features 
prevalent in the CKD population. With aggressive reduction of blood 
pressure in these subjects there would be an expected reduction in renal 
and cardiovascular risk. However, in a group with already well 
documented cardiovascular dysregulation (90,91), aggressive reduction 
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in blood pressure may potentially increase falls risk, resulting in further 
mortality and morbidity. 
Current Renal association guidelines recommend that in patients with 
CKD, systolic blood pressure should be lowered to <140mmHg with a 
target range of 120-139mmHg with a diastolic blood pressure 
<9OmmHg. For those subjects with diabetes mellitus or urinary protein 
losses of > 1 g/day, systolic blood pressure should be lowered to 
<130mmHg with a target range of 120-129mmHg and diastolic blood 
pressure <80mmHg. However, given the evidence from recent data 
relating to the potential dangers of excessive blood pressure reduction 
and the potential for exacerbating other features within the CKD 
population that might predispose to further mortality/morbidity, the 
emphasis is that antihypertensive treatment should be individualised. 
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2 HYPOTHESIS, AIMS AND PLAN OF 
INVESTIGATION 
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HYPOTHESIS, AIMS & PLAN OF INVESTIGATION 
This thesis has been planned to test the following hypothesis: 
Chronic kidney disease (CKD) is associated with profound alterations in 
body composition. These have far reaching consequences at cellular 
and systemic level and can adversely effect overall patient function 
across the entire range of CKD. We hypothesise that therapeutic 
interventions commonly utilised in this population may compound these 
functional anomalies. 
Research questions 
To test this hypothesis, the following research questions will be 
addressed: 
1. Does goal directed antihypertensive therapy in older subjects 
with predialysis CKD result in reduced functional status, 
Significant disturbances in body composition and increased falls 
risk? 
2. Do serum intact parathyroid hormone assays reflect dynamic 
measurements of bone collagen formation rates in prevalent 
male haemodialysis patients? 
3. What is the effect of calcium containing and non-calcium 
containing phosphate binder medication on dynamic 
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measurements of bone collagen formation and expression of 
osteotropic factors in prevalent male haemodialysis patients? 
4. Does non-invasive measurement of cardiovascular parameters 
in prevalent haemodialysis patients undergoing pharmacological 
stress permit identification of the dominant functional 
abnormalities that might predispose to intradialytic hypotension? 
5. How does haemodialysis impact on skeletal muscle total 
camitine depletion over the first 12 months of treatment in 
incident haemodialysis patients? 
6. Is this camitine deficiency associated with a reduction in 
exercise tolerance? 
7. Does this camitine defiCiency result in myocardial dysfunction? 
8. Does camitine supplementation impact on exercise tolerance or 
cardiac functional status? 
Plan of investigation 
4 separate investigational studies were designed with the aim of 
answering the above questions. 
• Body composition, cardiovascular and functional consequences of 
chronic kidney disease in older people. 
• Bone collagen formation rates and expression of osteotropic factors in 
male CKD 5 subjects undergoing haernodialysis 
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• Myocardial contractile function and intradialytic hypotension 
• Prospective study of the determinants of secondary camitine depletion 
and the skeletal and cardiac functional effects of L-camitine 
supplementation in incident chronic haemodialysis patients 
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3 METHODS 
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METHODS 
Methodology is described in detail in this chapter and then referred back 
to for reference in the relevant results sections. Certain methods and 
techniques were used in more than one study. 
3.1 Measurement of Body Composition 
BIA 
Bioelectrical impedance analysis was performed using the InBody S20 
(Biospace Ltd, Korea) mutlichannel, multisegmental analyser. 
This provided data on intracellular/extracellular fluid ratios, skeletal 
muscle, bone and fat mass for the whole body, and also segmentally for 
trunk and each limb. 
Initially we requested that subjects remove all metal jewelry as this has 
the potential to affect impedance measurement. Subjects were then 
required to lie in a 300 supine position (as recommended by the 
manufacturer). After cleaning the skin to ensure good contact, adhesive 
pads provided by the manufacturer were attached to the palmar aspect 
of the terminal phalanx of the middle fingers and thumbs on both hands, 
and to the lateral malleolus and 2nd metatarso-phalangeal joints of both 
feet. The placement of the adhesive pads was standardised in each 
subject to ensure good reproducibility of the measurements. Electrodes 
in the form of crocodile clips were then connected to the BIA unit via the 
adhesive pads. Demographics such as age, gender, height and weight 
were entered as requested prior to measurement. Race specific option 
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was also available and could have been used for subjects of Afro-
Caribbean and Asian origin. During the measurement period, subjects 
were requested to lie still. An undetectable alternating current was then 
passed through the subject's body. The analyser then transformed the 
electrical data mathematically to specific body composition outputs. 
Once subjects had been connected to the electrodes the technique was 
fully automatic. Intra-observer variability was therefore reduced as a 
consequence. The manufacturers claim a measurement error of 1 % 
with reproducibility of 99%. It has been successfully validated against 
the 'gold-standard' of deuterium dilution for total body water (TBW) 
assessment (92), and has been used as the reference in published 
research on TBWequation (93). It has also been validated against 
DEXA for total and regional body composition in healthy subjects (94) 
and peritoneal dialysis patients (95). 
DEXA 
DEXA was performed using available equipment in the University of 
Nottingham at Derby (Lunar Prodigy; GE Healthcare, Slough, UK). 
Scans were performed by Mrs Margaret Baker, clinical assistant, who 
had received appropriate radiation protection training to operate the 
scanner. 
Prior to scanning subjects were asked to empty their bladder. They were 
asked to remove heavy clothing and wear an examination gown. Full 
body DEXA was then performed with the subject lying supine and 
specific body composition measurements generated by the scanners 
44 
inbuilt software. Body composition data were then manually downloaded 
by the investigator. 
Servicing and calibration are managed by the University. DEXA is a 
clinical procedure, and thus has excellent reproducibility. 
Computed Tomography 
Muscle and fat Cross-sectional area were Simultaneously assessed by a 
multi- slice spiral CT scan. Studies were performed using a clinical 
scanner at Royal Derby Hospital (GE Medical Systems Ughtspeed 16 
multi-slice spiral CT scanner). Scans were performed by trained 
radiographers from the department of Radiology. Scans were taken 
through a standardised section of the right thigh, 20cm above the tibial 
plateau, 5 em in length, imaged in 2.5mm slices, with care taken to 
ensure that none of the slices overlapped. This did not require either 
intravenous or oral contrast. 
Muscle and fat CSA were then measured by the investigator using GE 
Medical Systems Advantage Workstation software with appropriate 
windowing for tissue density (fat and non-contractile connective tissue -
200-0 Hounsfield Units, muscle 0-200 Hounsfield units.) CSA was 
measured at the top, middle and bottom slices of this cylinder of thigh 
and the mean of these three values then adjusted for height . This 
technique has been used previously in our group (96). 
This technique also permits assessment of vascular calcification within 
the segment of superficial femoral artery found within the scanned field. 
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3.2 Functional assessments 
TUG test 
Simple assessment of patients' functional status was undertaken. We 
used the "Timed get-Up and Go· (TUG) test (97). This involved the 
patient rising from a chair (of a standard height), walking 3 metres, 
turning and returning to sitting. The movement was explained and 
demonstrated and the patient habituated to the procedure. Patients were 
then timed whilst performing this procedure once. This technique has 
been extensively used in falls research, and is well validated against 
more detailed assessments. 
Shuttle walking test 
Subjects were required to attend one week prior to commencing and at 6 
and 12 months after initiation of haemodialysis therapy, at the same time 
of day on each visit, to perform an incremental exercise tolerance test to 
volitional exhaustion. The exercise test was a standardised incremental 
shuttle walking test originally designed to provoke a symptom limited 
maximal performance in chronic obstructive pulmonary disease patients 
in order to provide objective measurement of disability (98). The test 
required the patients to walk back and forth along a flat 10 metre course, 
set out in a quiet corridor of the Royal Derby Hospital Medical School, at 
a gradually increasing speed, paced by audio signals (bleeps), until they 
were exhausted and/or could no longer keep up with the bleeps. Total 
distance walked was taken as a measure of aerobic exercise capacity, 
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as performance on the test relates strongly to V02max, the traditional 
indicator of aerobic capacity (99). 
Isomebic handgrip strength 
This assessment was carried out on the same visit as the incremental 
shuttle walking test. Isometric handgrip strength was measured using a 
dynamometer devised by Bassey et a!. (100). Patients were asked to 
squeeze a gripping bar with their dominant hand as hard as possible for 
-3 s. Each patient made three attempts with a rest of at least 1 min 
between attempts. The highest recording was taken as the measurement 
of handgrip strength. Verbal encouragement was given to each patient 
throughout. 
3.3 Tissue sampling 
Bone biopsy 
To assess fractional synthetic rate of collagen within bone in our male 
chronic haemodialysis population we performed bone biopsy. This was 
carried out by the investigator following appropriate training. Subjects 
were fasted from 8 p.m. the day before the study to reduce any effect of 
dietary protein on collagen formation rate. Approximately 120 minutes 
prior to the expected bone biopsy, basal blood samples and a skin 
biopsy from the groin crease for basal 13-Carbon levels (following 
infiltration of local anaesthetic) were taken. Following this 0.75g of [13C] 
Proline (99 Atoms %) and 3 g of unlabelled Proline were administered 
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over 5 min through an intravenous cannula. Blood samples were taken 
(using a second cannula) at 5 min intervals for 15 minutes and then 
every 15 minutes until the bone biopsy was taken. 
At 120 minutes a bone biopsy from beside the tibial tuberosity was 
taken. This was performed under local anaesthetic (lidocaine 1%). A 
small 1 em incision was· made in the skin over the shin, and then the 
biopsy taken using a standard bone biopsy tool (Bone Tenmo, 
Allegiance Medical, UK). The skin was then closed with sutures. These 
were removed one week later. 
The second bone biopsy was carried out according to the above outline. 
The only difference being that 0.75g of C5N] proline (99Atoms %) and 3g 
of unlabelled proline was administered in place of C3C] proline as an 
alternative marker. 
The bone, skin, and blood samples were coded and then frozen at-80 
degrees and stored until analysis for collagen and gene expression was 
carried out by the investigator in conjunction with laboratory staff located 
within the School of Graduate Entry Medicine, Derby. 
Muscle biopsy 
Muscle biopsies were performed one week prior to starting 
haemodialysis and at 6 and 12 months post initiation of therapy by the 
investigator having had appropriate training in the technique described 
by Bergstrom (101). Subjects who were anticoagulated, had abnormal 
clotting times or thrombocytopenia were excluded. Subjects were 
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requested to lie supine. The vastus lateralis biopsy site, at a point 25cm 
proximal from the tibial tuberosity and 5cm lateral from the midline of the 
femoral course was prepared with chlorhexidine solution. Skin and 
subcutaneous tissues were infiltrated with 5-10ml of 1 % lidocaine 
solution. After ensuring sufficient analgesia, a stab wound was made in 
the lateral thigh at the biopsy site, directly through the overlying skin, 
subcutaneous fat and fascia lata. A 6mm Bergstrom biopsy needle was 
then inserted through the fascia and advanced to ensure that the cutting 
chamber window was lying fully within muscle. An assistant then applied 
suction to the biopsy needle to improve biopsy yield. The biopsy was 
then taken. Samples were snap frozen in liquid nitrogen. The process 
was repeated up to a maximum of three passes to obtain sufficient 
muscle for analysis. The wound was sutured and a dry dressing applied. 
Sutures were removed by the investigator 7 days later. Muscle samples 
were processed and analysed by Dr Francis Stephens and laboratory 
staff from the Centre for Integrated Systems Biology, University of 
Nottingham, for relative camitine content. Results were analysed by the 
investigator. 
3.4 Haemodynamic data collection 
Finometer 
Continuous measurement of haemodynamic variables during 
haemodialysis sessions was performed using the Finometer. 
The Finometer (Finapres Medical Systems, Amhem, Netherlands) is a 
tool for blood pressure and haemodynamic monitoring. The advantage 
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of the Finometer is that it is accurate and robust and provides 
continuous measurement of multiple cardiovascular variables in one 
device. As a result, it is a versatile, non-invasive monitoring system that 
measures multiple haemodynamic variables on a beat-to-beat basis. 
The accompanying BeatScope® software allows online monitoring, 
control. storage and offline review of all the data on a PC. 
The Finometer is particularly useful due to its non-invasive nature and 
ability to provide continuous readings over a period of several hours. 
The Finometer works by continuous pulse-wave analysis at the digital 
artery and utilises the finger-clamp method, in which changes in digital 
arterial diameter are detected by means of an infrared 
photoplethysmograph (102) and opposed by an ultra-fast pressure servo 
controller that changes pressure in an inflatable air bladder. both 
mounted in a finger cuff. This generates an arterial waveform that is 
measured on a beat-to-beat basis and is used to reconstruct a central 
aortic waveform (103). This allows calculation of a full range of 
haemodynamic variables on a continuous basis; these include pulse rate 
(HR). blood pressure (BP). stroke volume (SV). cardiac output (CO) and 
peripheral resistance (TPR). All data are subsequently downloaded to 
the PC based analysis program, allowing averaging of results over 
defined time periods. This technology provides unprecedented resolution 
of changes in the critical cardiovascular variables. Previous work has 
validated the Finometer against invasive haemodynamic measurements 
in normal individuals. unstable intensive care patients and in cardiac 
surgery patients. a proportion of whom had vascular calcification (103, 
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104, 105). This has shown the Finometer to be accurate in tracking 
relative change. Data are therefore presented as percentage change 
from baseline except for BP, which is calibrated against brachial 
readings using a return to flow method and absolute values can 
therefore be used (106). 
3.5 Haematological and Biochemical parameters. 
All blood specimens were sampled by the investigator. All routine 
haematological and biochemical assessments were performed by staff 
within the department of Haematology and Biochemistry at Royal Derby 
Hospital unless otherwise stated. 
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4 CHANGES IN BODY COMPOSITION AND 
FUNCTIONAL CONSEQUENCES OF 
GOAL DIRECTED ANTIHYPERTENSIVE 
TREATMENT IN OLDER SUBJECTS 
WITH CKD 
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4.1 Introduction 
Significant CKD affects approximately 5% of the UK population. The 
prevalence of CKD rises dramatically with age. Based on the results of 
the National Health and Nutrition Examination Survey 1999-2004, more 
than one third of those aged 70 years or more have CKD 3 or higher 
(107). Older patients are less likely than younger subjects with similar 
levels of eGFR to progress to ERF and require renal replacement 
therapy (108, 109). The majority of patients in this age group will 
maintain relatively stable reduced renal function or die from competing 
mortality, in particular cardiovascular disease (108-11). 
CKD is associated with a wide ranging set of clinical consequences. 
There is an increasing evidence base between these sequelae and 
drivers for increasing cardiovascular pathology such as vascular 
calcification (45,112-3); malnutrition, inflammation and atherosclerosis 
complex (MIA) (34,114); alteration in adipokine profiles (115) and 
increasing blood pressure dysregulation (45,112). Disturbances in 
skeletal metabolism and function with increased fracture potential are 
common (116,117). CKD is associated with both muscle wasting (5, 6) 
and reduced functional capacity (118) that seem to progress with the 
degree of renal impairment. This has previously been demonstrated in a 
study by MCintyre et al (2006), in which subjects with dialysis treated 
CKD 5 exhibited more functionally significant muscle wasting than 
patients with CKD 4 (96). 
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The process of aging itself is associated with a well defined set of 
changes in body composition. Throughout life human muscle undergoes 
constant changes. However after the age of 50 years, muscle mass 
decreases at an annual rate of around 1-2%. Muscle strength declines 
by 1.5% between ages 50 and 60 and by 3% thereafter (119). 
Degenerative bone disease and osteoporosis are increasingly common 
with advancing age and associated with increasing mobility problems 
and fracture risk. 
The major management challenges in older CKD subjects relate to 
reduction in cardiovascular risk factors. Crucially, the cornerstone of 
management is aggressive treatment of hypertension. Blood pressure 
control has been shown to be problematic for persons aged ~ ~ 70 years 
and in individuals with CKD. Prevalence rates of hypertension in older 
subjects range between 60 to 80% (120). Several large studies looking 
at blood pressure reduction, speciftcally in older subjects, have 
demonstrated an associated reduction in death rate from stroke and 
cardiovascular disease with improved blood pressure control (121, 122). 
It has been demonstrated in several large trials that blood pressure 
lowering has a more significant effect on renal progression in subjects 
with significant proteinuria. In this setting the use of angiotensin 
converting enzyme inhibitors and angiotensin II receptor antagonists 
have more relevance. However, most trials investigating the potential 
benefits of these drugs did not include subjects above the age of 70 
(123). This is an important issue given that older subjects are more likely 
to have adverse side effects from therapy, such as hyperkalaemia or 
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acute kidney injury. Age-related declines in baroreflex sensitivity to 
hypotensive stimuli, manifest by failure to increase heart rate when 
blood pressure falls and reduced basal renin and aldosterone levels 
potentially promoting the development of volume depletion are some 
examples of fadors that could be aggravated by antihypertensive 
medications in this group of subjeds with an already well recognised 
charaderistic cardiovascular dysregulation. 
The National Service Framework for Older People reported that hip 
fradures associated with falls resulted in an annual NHS financial cost of 
£1.7 billion. There is a paucity of evidence relating to the potential 
effeds of goal direded antihypertensive treatment in this group in 
relation to body composition, function and falls risk. 
This investigational study was carried out jointly with Dr Stephen John 
who will use data relating to measurement of cardiovascular parameters. 
not documented here. at the same investigational study visits. as part of 
another thesis. The body composition, fundional assessment, falls data 
and blood pressure response are presented here. 
4.2 Aims 
We hypothesised that pursuit of an optimal antihypertensive strategy in 
the older patient with CKD may result in an increased propensity to falls 
and be associated with clinically important changes in body composition, 
cardiovascular fundion and overall fundional status. 
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The principle aims of this study were: 
• To observe effects on body composition and functional assessment from 
baseline following antihypertensive withdrawal and at 4 weeks and 12 
months following blood pressure (BP) optimisation in a group of 
hypertensive subjects aged >70 years with CKD 3, CKD 4 and aged 
matched non CKD controls. 
• To document falls rate in this group of subjects over a 12 month period 
following blood pressure optimisation. 
4.3 Methods 
4.3.1 Subjects 
We recruited volunteers from outpatient clinics at the Royal Derby 
Hospital and from GP practices in the Southem Derbyshire and Derby 
City regions who were hypertenSive (BP> 130/80), aged ~ 7 0 0 years with 
either CKD 3, CKD 4 or normal renal function (eGFR>6Omlslmin for 
purposes of this study). Patients were excluded from the study if they 
met any of the following criteria: 
• Use of more than 3 drugs for blood pressure control at recruitment 
• Likely to develop CKD 5 within one year 
• Poor mobility precluding completion of assessment 
• Diabetes 
• Abbreviated mental test score <8 
• Recent acute illness (within 3 months) 
• Ischaemic heart disease requiring beta-blockade 
• Involvement in another clinical trial within 3 months 
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• Attending day hospital or attending falls reduction services 
• Residents in nursing or residential homes 
• Renovascular disease precluding ACE-inhibitor or Angiotensin Receptor 
blocker usage 
• BP > 160/90 prior to antihypertensive withdrawal 
• Malignant hypertension 
• Severe peripheral vascular disease or significant valvular heart disease 
• Heart failure (NYHA Ill/IV) or other cause to prevent diuretic withdrawal 
• Atrial fibrillation or other significant arrhythmia 
• Currently taking antihypertensive medication for which MHRA approval 
(eTA) has not been granted 
• Obstructive uropathy 
The study was approved by the Southern Derbyshire Local Research 
Ethics Committee with clinical trial approval (CTA) from the MHRA. 
Before taking part in the study, all subjects gave their written informed 
consent to participate and were aware that they were free to withdraw at 
any point. 
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4.3.2 Experimental Protocol 
Figure1 summarises the study schedule. After identifying potential 
participants and providing them with information about the study they 
were invited for a recruitment visit one week later. At this stage informed 
consent was obtained. An appropriate medical history was taken and 
clinical examination performed which included BP measurement. 
Providing that subjects met the above criteria they were given a plan to 
reduce and stop antihypertensive medication during a 4 week washout 
period. They were given an appropriately calibrated, serviced and 
approved oscillometric device to perform daily home BP measurements. 
They were reviewed at two weeks to ensure that they had not developed 
any Significant problems. If systolic blood pressure (SBP) was greater 
than 180mmHg or diastolic blood pressure (DBP) greater than 
110mmHg they were withdrawn from the study and antihypertensive 
medications were restarted. Following the washout period subjects 
attended for their first investigational visit. BP was measured at rest. 
Subjects provided a urine sample for quatification of urinary protein to 
creatinine ratio. Blood samples were obtained for measurement of FBC, 
U&E, bone profile, albumin, CRP, PTH and Vii: D. Body composition was 
assessed using whole body dual energy x-ray absorptiometry (DEXA) , 
whole body bioelectrical impedance analysis (BIA) and thigh fat and 
muscle surface area were assessed using multi-slice spiral CT scanning. 
Finally a "timed up and go" (TUG) test was performed as a marker of 
functional state. 
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Visit 1 
Visit 2 
Visit 3 
Subjects were then given a plan to restart antihypertensive therapy with 
daily home BP monitoring aiming for a target blood pressure S130/80. 
Patient Identification In Outpatlentsl GP PractIce 
· 
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Figure 1. Study plan 
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They were reviewed every 14 days to assess response and medications 
adjusted accordingly. Having achieved target BP subjects continued 
their antihypertensive regimen for 4 weeks before returning for their 
second investigational study visit. The tests undertaken at this point are 
listed in Figure 1. 
Subsequently subjects' medications were left unchanged. Their GP was 
instructed to make any particular adjustments as necessary based on 
clinical need. Subjects were asked to complete and return a falls diary 
each month for the next 12 months. 
After 12 months subjects were invited back to repeat the series of tests 
carried out at their initial investigational visit. 
4.3.3 Blood Pressure 
The study involved both removal of antihypertensives and later 
reintroduction to best practice levels of blood pressure control (:S130/80). 
1. Measurement 
a. Measurement was performed with an appropriately calibrated, 
serviced and approved oscillometric device. 
b. At recruitment visit BP was be measured in both arms. The arm 
with the higher reading was used for all subsequent measurements. 
c. At all visits 3 measurements were performed, at least 2 minutes 
apart. The mean value was used for further analysis. 
d. Postural BP was also recorded at all visits. A single set of 
measurements were taken at sitting (0), 1, and 3 minutes (124). If 
there was a postural drop of > 20/10mmHg, antihypertensive 
agents were reduced and the patient's GP informed. 
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e. Other aspects of measurement were performed to current best 
practice guidance. 
2. Washout 
a. BP increased during this period. The risk to the patient from this 
was low. Subjects monitored their BP daily at home, and had their 
BP checked at hospital after 2 weeks. If SBP was> 180 or DBP > 
110, their antihypertensives were restarted and were withdrawn 
from the study and their GP informed. 
b. The rise in BP during washout and the speed that agents were 
changed related to the number of antihypertensive agents that a 
patient was originally taking. 
c. Patients taking 4 or more agents have difficult to manage 
hypertension, and it was felt would have a higher risk of developing 
severe uncontrolled hypertension on withdrawal. 
d. We therefore limited this study to patients taking a maximum of 3 
antihypertensive agents. 
e. Antihypertensive agents were stopped singularly, with a period of 
48 hours between agents. Beta-blockers were stopped gradually, 
by halving the dose, where practical, every 5 days. 
3. Reintroduction 
a. Patients were taking at least one antihypertensive agent prior to 
washout. 
b. Reintroduction commenced at visit 1. 
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c. We returned BP to a level of control at least equivalent to baseline. 
Ideally, this will be :S130/80. 
d. If BP became <110/60 after an increase in treatment, the increase 
was reversed. 
e. We used the known list of medications that individual subjects were 
taking at recruitment to guide reintroduction. 
f. Similar to withdrawal, patients on multiple agents had them 
reintroduced at 48 hour intervals. 
g. We aimed to use agents using best practice guidelines (125,126). 
h. BP was monitored at a hospital visit every 2 weeks during 
reintroduction. 
i. A period of one month on stable medication was required before 
visit 2. 
j. We checked U+E at initiation, one week and one month after dose 
titration of ACEilARB, where patients were na"ive to these agents. 
k. If we needed to introduce an ACEi, our preferred agent was 
ramipril. 
4.3.4 Body composition 
Whole body DEXA, BIA and thigh computed tomography was performed 
following antihypertensive withdrawal and at 12 months post blood 
pressure optimisation (visit 1 and visit 3). BIA assessment of body 
composition was also repeated at visit 2 post blood pressure 
optimisation. 
Detailed descriptions of the specific methods used are found in chapter 
3. 
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4.3.5 Functional assessment 
To assess general function a timed get up and go test (TUG) was 
performed at each investigational visit. A detailed description of this test 
is found in chapter 3 (97). 
4.3.6 Falls Diary 
In keeping with the 2005 consensus statement on falls research (127), 
the definition of a fall in this study was "an unexpected event in which 
the participants come to rest on the ground, floor, or lower level". 
Any history of falls over the sixth months prior to recruitment was 
documented at the initial assessment. To capture all falls subjects were 
asked to complete a prospective daily falls diary once established at 
target blood pressure. These were collected on a monthly basis for a 
twelve month period. Participants were given the diaries and asked to 
enter events that included a slip or trip resulting in a fall as well as other 
falls events as recommended in the consensus statement. 
4.3.7 Laboratory Tests 
Analysis of plasma and serum for FBe and routine biochemistry was 
carried out by staff within the Haematology and Biochemistry 
Laboratories at Royal Derby Hospital. 
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4.3.8 Statistical analysis 
Data were analysed using GraphPad Prism 4.02 (GraphPad Software 
Inc, CA). Data were checked for normal distribution and unless 
otherwise stated were expressed as mean +/- standard deviation. 
Unpaired student's t-test was used to compare data between groups and 
paired t-test to compare data over time. Pearson's correlation was used 
to compare assessment methods and Bland-Altmann plots generated. 
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4.4 Results 
I 
[ 
I 
i 
I 
I 
I 
I 
I 
I 
I 
Patients 
60 subjects attended for an assessment visit. All of these were initially 
entered into the antihypertensive withdrawal phase. Unfortunately 6 
subjects had to be withdrawn from the study as their blood pressure 
recordings during this phase exceeded our previously stated limits for 
safety. 
A ( ge years 
Male: Female ratio 
Number of 
antihypertensive drugs 
Percentage with history of 
fall 
within last 6 months 
I 
I 
I 
I 
I 
Non-CKD 
(n=25) 
761 
1.25: 1 
1.72 
22% 
I 
I 
CKD 
(n=29) 
757 
1.25: 1 
1.76 
17% 
Pvalue 
074 
i 
I 0.95 
I 
0.85 
0.06 
I I I 
eGFR mis/min 87.7 42.9 I <0.0001 I i I 
Urine Protein: Creatinine I 0.12 0.31 I 0.03 I 
Ratio (mgIrng) 
Haemoglobin (g1dl) 13.9 12.7 0.008 
SSP (mmHg) 152.8 153.0 0.97 
DBP (mmHg) 80.8 79.6 0.65 
Weight (Kg) 75.8 73.9 I 0.62 
27.2 26.7 I 0.61 
Table 2. Basic demographic data for subjects following withdrawal of antihypertensive 
agents 
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Table 2 demonstrates demographic features and some baseline 
parameters of the remaining 54 subjects at their first investigational visit 
following withdrawal of antihypertensive therapy. Data are expressed as 
mean values unless otherwise stated. 
There were no significant differences between groups in terms of age, 
male to female ratio, previous antihypertensive load, previous falls 
history, blood pressure recordings, weight and BMI. As would be 
expected the CKD group demonstrated higher urinary protein loss and 
mildly reduced haemoglobin. 
All 54 subjects subsequently went on to have antihypertensive therapy 
reintroduced to achieve target blood pressure and repeat assessment at 
visit 2. Unfortunately during the 12 month period before visit 3 one non-
CKD subject died. Two CKD subjects were unable to attend for their final 
investigational visit due to spousal ill health but they did return a 
complete set of falls diaries. 
Blood Pressure 
At assessment, mean average recorded SBP and DBP for the 54 
subjects who successfully completed the withdrawal phase was 
142mmHg and 75mmHg respectively with a mean number of 1.7 
antihypertensive agents. On withdrawal of these drugs, values rose to 
153mmHg and 80mmHg for SSP and DBP. 
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Drug Class Non-CKD 
(% use) 
ACEi/ARB 50 
Alpha Blocker 21 
Beta Blocker 33 
I 
i 
Calcium Channel Antagonist !! 38 
ii 
Diuretic i 42 
Table 3. Percentage use drug class by group 
~ ~
:1 I All I SBP mmHg II 
participants (sta.nd.ard II 
I I deViation ~ ~ I' 
I I OBP mmHg II 
: (standard II 
i 
I CKD 
I Non-CKD 
I 
I d e v i a t i o n ~ ~ II 
Number of ii I i AHTagents 
I SBPmmHg 
I (standard 
i deviation) 
i OBPmmHg 
I (standard 
I deviation) 
I
, Number of 
, AHTagents 
i SBPmmHg 
I (standard 
i deviation 
I 
, DBP mmHg 
! (standard 
I deviation) 
I Number of 
I AHT agents 
Assessment 
Visit 
142 
(12) 
75 
(8.6) 
1.7 
139 
(13) 
74 
(9) 
1.8 
146 
(10) 
76 
(8) 
1.7 
I 
I 
I 
I 
I 
I 
J 
V1 
(Withdrawal) 
153 
(19) 
80 
(10) 
0 
153 
(21) 
80 
(10) 
o 
153 
(16) 
81 
(10) 
o 
CKD P 
I 
(%use) value I 
67 0.227 1 
19 0.8351 
19 0.226 1 
41 0.813 I 
33 0.539 
, V2 (Treated V3 (12 
I to target) months) 
! 129 131 
I (14) (15) 
I 
69 69 
(8) (7) 
I 
1.8 1.7 
130 129 
(16) (16) 
I 
i 69 68 
(9) (7) I 
I 
1.8 1.7 
129 134 
(12) (13) 
69 71 
(7) (6) 
1.9 1.6 
Table 4. Mean SBP, DBP and number of antihypertensive agents across study period 
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! 
I 
I 
I 
i 
I 
I 
I 
I 
Tabte3 illustrates the percentage use of specific drug class at 
reintroduction. There were no significant differences in drug class usage 
between groups. 
Following careful reintroduction of medications to achieve target BP of 
:S130/80 or at least equivalent of initial control, mean SBP and OBP 
recordings were both significantly lower than at the initial assessment 
visit. Values were 129mmHg (p<O.OOO1) and 69mmHg (p=O.0002) 
respectively. The antihypertensive drug load was marginally higher at a 
mean of 1.8 drugs (range 1-3) but this was not statistically Significant. 
This data is summarised in Table 4 along with a breakdown of response 
based on grouping according to renal status. 
There were no adverse events reported during the antihypertensive 
reintroduction phase or over the 4 week period once established at 
optimal blood pressure. 
Over the next twelve months no routine checks of BP or adjustments to 
medication were initiated by the study group. PartiCipants remained 
under the care of their general practitioner and had any appropriate 
health checks and medication reviews as per normal practice. Blood 
pressure readings taken at visit 3, 12 months after visit 2, showed that 
the initial improvement to overall blood pressure control during the initial 
stages of the study appeared to have been maintained (mean SBP 
131mmHg, mean DBP 69mmHg). There was no Significant difference 
between recordings at these two time points. 
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Renal Parameters 
V1 V2 V3 
I Number of 
CKD I subjects 29 29 27 
~ I I - - - = C ~ - ~ ~ t ~ i n ~ i n - e ~ ~ - - - - - - - - - - + - - - - - - - - - - + - - - - - - - - ~ ~
I (SO) 144 (57) 150 (61) 155 (57) 
I lJmoVL 
I 
eGFR 
(SO) 
I mis/min 
43 (14) 42 (14) 41 (15) 
mg/mg [ I 
• 
i 
I 
Number of 
II Non- subjects il 25 25 24 CKO, C r ~ t i n i n e e I! I 
I I (SO) 'I 72 (19) I 73 (17) 80 (20) 'I ~ m o l / L L I I 
I 
,I 
i eGFR II I I 
I 
uPCR 
(SO) 0.31 (0.41) 0.30 (0.47) 0.26 (056) 
88 (17) 86 (15) 80 (14) * 
0.12 (0.1) 0.11 (0.1) 0.11 (0.1) i 
* reduction eGFR V2 to V3 p=0.01 
Table 5. Creatinine, eGFR and uPCR expressed as mean over study period 
Values for serum creatinine, eGFR and uPCR for the study period are 
shown in table 5. Over the course of the study there were no significant 
changes in these parameters within the CKD group. However, within the 
Non-CKD group serum creatinine increased resulting in a significant 
decline in eGFR (p=O.01) over the 12 month between blood pressure 
optimisation and visit 3. Urinary protein losses were unchanged. The 
relative reduction in eGFR over this time period would be in excess of 
that expected due to renal senescence. 
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Muscle, Bone and Fat Mass 
BMI did not change significantly within or between groups over the study 
period. Table 6 demonstrates measured Muscle, Fat and Bone mass 
over the study period by both BIA and DEXA. 
Wrthin the CKD group muscle mass decreased significantly between V1 
and V3 as measured by both BIA and DEXA (p=0.007 and 0.02 
respectively). This decline could equate to either a mean percentage 
reduction of 3% or 0.4% depending on the technique used (BIAIDEXA 
respectively). BIA assessment of muscle mass also demonstrated an 
average reduction of 2% within the Non-CKD group between V1 and V3 
(p=0.015). This was not confirmed by DEXA which demonstrated no 
Significant change. 
There were no significant changes in body fat mass demonstrated by 
either technique over the study period. 
Bone mass as measured by BIA reduced in both groups between V1 and 
V3. This was not confirmed by DEXA measurements. These suggested 
no significant change over time. However, dividing the total group by 
sex, both males and females demonstrated a small reduction in bone 
mass between V2 and V3. With BIA in men, bone mass reduced by a 
mean of 122g and in females by 78g. with DEXA male bone mass 
reduced by 110g and 28g in females. This only reached significance in 
the BIA measurement for males (p=0.02). 
There were no Significant differences between measurements of muscle, 
fat or bone mass between V1 and V2 on BIA measurements. 
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MUSCLE MASS i 
I BIAgrams 
CKO I (SO) I I 
I I 
I 
DEXA grams ! 
. (SO) I 
BIAgrams 
i Non- I (SO) 
I CKO 
. OEXA grams I I (SO) 1 
! 
FAT MASS 
BIAgrams 
CKD (SO) i I 
, DEXA grams I 
! (SO) I 
I BIAgrams I 
Non- I (SO) I 
CKO I OEXA 
I I 1 
I 
BONE MASS I 
BIAgrams i 
CKD I (SO) I 
I DEXA grams ! 
(SO) I 
! BIAgrams : 
Non- I (SO) i 
CKO I 1 
: DEXA grams I I (SO) 
V1 
46374 
(10194) 
44240 
(8641) 
46452 
(10037) 
44760 
(9666) 
V1 
24466 
(7868) 
25530 
(7762) 
26448 
(9368) 
26622 
(8880) 
V1 
2894 
(576) 
2699 
(653) 
2905 
(568) 
2600 
(603) 
* P=0.OO7, • P=O.02, 0 P=0.015 
V2 
I 45714 
(9798) I 
I 
45106 
(9226) 
V2 
23928 
(7503) 
26244 
(9508) 
V2 
2855 
(561) 
2838 
(486) 
V3 
44806* 
(10199) 
44058 
(8558) • 
454200 
(9622) 
45213 
(8925) 
V3 
25200 
(9121) 
25358 
(8632) 
27395 
(9241) 
26381 
(8832) 
V3 
2787 
(572) 
2722 
(675) 
2845 
(536) 
2475 
(746) 
TableS. Muscle, Fat and Bone mass expressed as mean value in grams (SO) by BIA I 
DEXA over study period 
Right thigh muscle cross-sectional area measurements corrected for 
height to give an approximation of right thigh muscle mass (96) 
demonstrated no Significant change between V1 and V3 as did regional 
DEXA. VVhen compared to regional DEXA measurement of right lower 
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I 
I 
I 
limb CT tended to give consistently lower estimates (r=0.7, ~ = 0 . 5 , ,
p<0.OOO1). 
Assessment of right thigh fat mass using CT cross-sectional area with 
height correction showed no significant change from V1 to V3 again in 
agreement with DEXA assessment. In the assessment of fat mass CT 
gave consistently higher estimates than DEXA (r=0.78, r2=0.6, 
p<0.OOO1). 
Comparison of DEXA and BIA assessment of body composition 
Direct correlation of measurements of muscle, bone and fat mass, taken 
at baseline, between DEXA and BIA derived data are illustrated in Figure 
2 ( ~ ~ values of 0.88, 0.68 and 0.82 for muscle, bone and fat respectively). 
Compared with DEXA, BIA demonstrated wide limits of agreement. 
In assessment of muscle and bone mass, BIA tended to provide higher 
values than DEXA. This difference appeared to increase with increasing 
subject weight (Figure 3). 
With regard to assessment of fat mass, BIA did not appear to 
demonstrate any specific systematic bias through the range of weights 
for the study population (Figure 3). 
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Bland-Altman BIA versus DEXA measured muscle mass 
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Body Wafer 
Taking the study group as a whole, mean total body water (T8W) fell 
between V1 and V2 (p=O.04) by a mean of 0.71. There was further 
decline over the following 12 month period by a mean 0.3L (p=0.02). 
Unsurprisingly, given the pharmacological actions of AHT medication 
used, ECF volume fell by a mean of 0.3L at visit 2 following 
antihypertensive reintroduction (p=O.03). There was further reduction in 
ECF by a mean ofO.1L over the following 12 months (p=0.03). 
Analysis of subjects by group (CKD/non-CKD) demonstrated no 
significant changes in body water at any stage during the study. 
Functional Assessment 'TUG' test and Falls 
TUG seconds (Standard deviation) ! 
V1 (WIthdrawal) I V2 (Treated to V3 (12 months) I 
I target) 
I 
I All I 9.2 (4.2) 8.9 (3.5) 10.0 (5.8)* participants I n=54 I n=54 n=51 
I I i 
CKD 9.9 (5.5) I 9.S (4.5) 11.3 (7.7). ! 
n=29 n=29 n=27 
Non-CKD I 
8.3 (1.3) 8.2 (1.3) 8.6 (1.5) 
n=25 n=25 n=24 
Change in TUG overtime * p=0.009, • p=0.03 
Table 7. Timed Up and Go Results (TUG) over study period 
For the group as a whole performance within the TUG test deteriorated 
slightly overtime (p=O.OO9). Although there was a large range of times (6-
33 seconds V1, 5-28 seconds V2 and 5-45 seconds V3) only 2 subjects 
had times above 20 at any point to suggest more severe functional 
7S 
I 
1 
i 
I 
I 
I 
problems. The proportion of subjects scoring in the range consistent with 
independent functional status «10seconds) feU from around 89% at the 
start of the study to 82% at V3. Looking at the eKD group alone TUG 
performance deteriorated (p=O.03). However, taken separately there was 
no significant change in performance in the non-eKD control group. 
These results demonstrate that both the non-eKD and eKD subjects 
have good functional status. This is reflected by data obtained from 
monthly falls diaries. In total only 27 episodes were reported involving 13 
subjects (6 eKD, 7 non-eKD). Range was 1-6. Documentation 
suggested a 'mechanical' or 'accidental' cause in aU instances. There 
was no association between TUG performance, BP or measures of body 
composition. 
4.5 Discussion 
This is the first description of both acute and chronic effects of goal 
directed antihypertensive therapy on body composition and functionality 
and long-term falls risk in a population aged ~ 7 0 0 years with and without 
eKD. 
With careful monitoring we were able to achieve the consensus target 
BP with a mean of 129169mmHg across the entire study group. This was 
achieved without promoting unwanted adverse symptoms or drug side 
effects. This improvement in BP control appeared to be lasting as it was 
still apparent at follow up visits 12 months later. 
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As might be hoped, this optimisation of BP control was associated with 
stability in renal function in the CKD group. Mean eGFR fell by 1 mUmin 
between V2 and V3 (p=ns) and urinary protein losses actually showed a 
minimal decline over the study period. This reinforces the importance of 
adequate antihypertensive intervention in the CKD population. Given that 
most of the major trials related to the use of ACE-I and ARB drugs did 
not include older subjects (123) these results provide extra evidence that 
in carefully selected older subjects with CKD, where these medications 
might be indicated, it is potentially safe to utilise them. 
Within the non-CKD group, it was observed that eGFR did decline 
significantly over the 12 month period following BP optimisation from a 
mean of 86mVmin to 80mVmin (p=O.01). Urinary protein losses were 
unchanged. This reduction is above that which might be expected due to 
renal senescence (-1-2mVmin/year). A potential explanation for this 
increased decline in eGFR is renal hypoperfusion due to reduced BP. A 
similar acceleration in decline of renal function has been observed in the 
ACCORD study in those subjects randomised to strict BP control 
«12OmmHg systolic) (84). This finding adds weight to the evidence that 
BP targets in the absence of CKD and Significant proteinuria should be 
higher. 
Body composition is important in the assessment of nutritional status, 
disease risk, physical fitness and effectiveness of interventions (128). 
DEXA is used extensively for the assessment of body composition and is 
considered valid and reliable (129). Its application is limited by 
requirements for expensive equipment, trained technicians and 
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dedicated facilities. BIA on the other hand is a relatively simple, 
inexpensive non-invasive and portable means of assessing body 
composition giving it a broad application. The correlations between 
measurements of muscle, fat and bone mass obtained in the present 
study are comparable to those from other studies (130). 
With respect to BIA obtained data, mean muscle mass was observed to 
decline in both CKD and non-CKD subjects over the 12 month period 
foUowing BP optimisation. The mean reduction was 3% and 2% 
respectively. The difference between groups was not Significant The 
reduction in the non-CKD group would be at a level with that expected 
due to age related deterioration over time (119). The decrease in the 
CKD group might be expected to be higher as a result of other factors 
resulting in muscle loss more specific to the uraemic setting. 
Equal numbers of CKD and non-CKD subjects were treated with ACE-I. 
Interestingly, those receiving ACE-I showed a reduction in muscle mass 
at 12 months by -1 %. Those not treated with ACE-I actually had an 
increase in total muscle mass -2%. These values did not reach 
statistical significance but are the opposite of what might be expected 
given the current evidence base for ACE-I reducing sarcopenia (131). 
In contrast to muscle, literature relating to fat mass in subjects with CKD 
is relatively sparse. The realisation that fat is more than an inert storage 
organ and may mediate inflammation via the effect of adipokines will 
hopefully increase the evidence base. We did not demonstrate any 
significant change in fat mass over the study period in either group 
irrespective of assessment method. 
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Most of an individuals bone mass is achieved by early adulthood. After 
that time, bone mass gradually declines throughout the rest of life. There 
is a normal rate of decline in bone mass with age in both men and 
women. For women, in addition to age, the menopause transition itself 
causes an extra degree of bone loss. This bone loss is greatest in the 
first three to six years after menopause. Women can lose up to 20% of 
the total bone mass during this time. Since women generally have a 
lower bone mass to begin with in comparison with men, the ultimate 
result is a higher risk of fracture in postmenopausal women as compared 
to men of the same age. The present study demonstrated a Significant 
decline in overall bone mass within male subjects. 
In terms of function, the present study has shown no deterioration over 
12 months in the non-CKD group but a Significant reduction within the 
CKD group. This may in part be related to the increased reduction in 
muscle mass in this group. However, this did not relate to falls risk. Falls 
are common amongst older people and a major public health concern in 
terms of morbidity, mortality and cost. The prevalence has been 
estimated as 28-35% in community dwelling older people aged 65 years 
and up to 42% in those aged over 75years (132). Falls occurred in 
approximately one quarter of our subjects over a twelve month period. 
Relatively this is actually quite low. This highlights one of the main 
problems with this study. Due to the strict criteria of entry we have 
excluded subjects who might be more prone to falling and therefore 
cannot really apply our findings to a broader population. However, we 
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have demonstrated that, in a carefully selected population of older 
subjects with CKD, the aggressive targeting of optimal blood pressure 
control to preserve renal function does not result in Significant problems 
with falls in this group. 
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5 BONE COLLAGEN FORMATION RATES 
AND EXPRESSION OF OSTEOTROPIC 
FACTORS IN PATIENTS WITH CKD 5 
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5.1 Introduction 
With progressive CKD characteristic disturbances in bone and mineral 
metabolism are common. These underlying biochemical disturbances in 
calcium, phosphate, vitamin 0 and PTH homeostasis associated with 
renal bone disease are apparent early. Bone tumover is predominantly 
under the influence of PTH. Uraemia is associated with a state of 
skeletal resistance. Secondary hyperparathyroidism is an almost 
inevitable consequence of untreated chronic kidney disease. Due to high 
circulating levels of PTH, both osteoblast and osteoclast surfaces are 
augmented and ultimately bone volume may be reduced (133). 
Synthesis of 1,25 dihydroxyvitamin 0 (calcitriol) is impaired in subjects 
with CKD. This occurs at least in part due to loss of renal parenchyma 
and in part due to suppression of 25-hydroxyvitamin D-1a-hydroxylase 
by retained phosphate and Fibroblast growth factor 23 (FGF23) (134). 
As a result, reduced levels of calcitriol develop from CKD3 onwards, 
leading to a reduction in calcium absorption (135). The effects of low 
levels of calcitriol and reduced extracellular ionised calcium on the 
parathyrOid gland lead to increased production of PTH. This will, initially, 
result in normalisation of calcium levels. Over time skeletal resistance to 
the calcaemic effect of PTH develops. Subsequent abnormalities in 
mineralization, bone morphology and electrolyte homeostasis, due to the 
inability of the skeleton to adequately buffer the internal milieu, 
predispose to bone pain and increased fracture potential, in addition to 
increasing drivers for vascular calcification. 
82 
To avoid renal bone disease and provide adequate skeletal activity to 
buffer the internal milieu, therapeutic interventions are directed towards 
ensuring normalised bone turnover. PTH levels are used as a surrogate 
biomarker to predict bone turnover in eKD patients. 
5.1.1 Diagnostic Dilemmas 
To date, the gold standard for the accurate diagnosis of renal bone 
disease remains histomorphometric and histochemical examination of a 
bone biopsy specimen. 
Bone is typically obtained from the iliac crest after the administration of 
time-spaced tetracycline markers to determine the rate of new bone 
formation (136). The typical labelling schedule involves two three day 
periods of tetracycline labelling separated by 21 days. The main 
drawback with this technique is its invasive nature. This has limited its 
use primarily as a research tool. Another problem is that it does not 
reliably provide information about acute changes in bone collagen 
dynamics and its response to physiologicaVpathophysiological stimuli. 
Measurements of the concentration of PTH in serum or plasma are 
widely used for initial diagnostiC assessment, monitoring of progression 
and response to treatment of patients with renal bone disease. The 
different methods and assays available for measuring PTH in biological 
samples create a possible source of confusion for clinicians (137). First 
generation immunometric PTH assays (intactliPTH assays), were 
thought to detect predominantly full-length, biologically active 1-84 PTH. 
It is now known that most of these assays also detect one or more 
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amino-tenninally truncated peptides distinct from 1-84 PTH in addition 
(138, 139, 140). These assays therefore overestimate the concentration 
of 1-84 PTH. 
Current clinical guidelines for the treatment of patients with CKD are 
largely based on the recommendations published in 2003 by the 
KidneylDialysis Outcomes Quality Initiative (KlDOQI). Two thirds of 
these recommendations are based on clinical opinion rather than direct 
experimental data. 
Most of the data used to derive target levels for PTH at different stages 
of CKO originates from clinical studies of the relationship between 
plasma PTH levels and bone histology in patients on dialysis during the 
1980s and early 1990s. These reflect the impact of therapeutic 
strategies, diagnostic tests and the demographics of the dialysis 
population during this period (137). Aluminium containing phosphate 
binders, which were used predominantly at this stage, are now rarely 
utilised. They have largely been replaced by calcium salts which can 
directly affect PTH levels. A study of patients on chronic maintenance 
dialysis in 1995 showed that bone turnover could not be predicted by 
serum PTH measurements in 30% of haemodialysis and 51.3% of CAPO 
patients (141). The authors proposed that to precisely assess bone 
turnover in patients with serum PTH levels between 65 and 450pg/mL, 
bone biopsy is required. 
A separate issue with current guidelines is that there is little direct 
experimental data for patients with CKO not yet requiring dialysis. A 
study of 84 patients with ERF not yet started on dialysis, comparing the 
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histomorphometric and histochemical analysis of bone biopsy specimens 
to different plasma biochemical markers, showed that iPTH levels did not 
correlate significantly with any bone histomorphometric or histodynamic 
parameter (142). 
5.1.2 Novel Investigational Technique 
Professor Rennie's group developed a technique to study the direct, 
dynamic measurement of human bone collagen synthesis rate within 
hours. It depends on measuring the incorporation of a stable (non-
radioactive) labelled collagen precursor ([13C] or C5N] proline) into 
hydroxyproline in bone. (The techniques are described fully by Babraj et 
al 2002 (143». The technique utilises an initial skin biopsy to determine 
basal 13C/15N levels, which have previously been shown to be similar to 
those of bone collagen in non uraemic subjects (143), and therefore only 
requires a single bone biopsy of around 150mg after administration of 
tracer. The technique requires only 50 mg of bone and should leave 
adequate sample for RNA extraction and real time Polymerase Chain 
Reaction (PCR) of biologically relevant genes. 
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5.2 Aims 
Utilising this new technique our primary aims were to investigate: 
1. Bone collagen synthesis rate (CSR) in a cross section of prevalent 
male haemodialysis patients, having washed off from both vitamin D 
and oral phosphate binding therapies to determine the level of PTH 
that best replicates bone formation in healthy individuals. 
2. The direct effects on bone CSR of phosphate normalisation with 
either calcium (Calcichew) or non-calcium containing phosphate 
binders (Sevelamer), with equal control of serum phosphorous. 
Our secondary aim was to observe the effect of phosphate normalisation 
on expression of biologically relevant gene markers of bone turnover. 
5.3 Methods 
5.3.1 Subjects 
We recruited male chronic haemodialysis patients from the 
haemodialysis program at Royal Derby Hospital. The study was 
approved by the Southern Derbyshire Local Research Ethics Committee 
in accordance with the Declaration of Helsinki. Before taking part in the 
study, all patients gave their written informed consent to take part in the 
study and were aware that they were free to withdraw from at any point. 
Patients were excluded if they were less than 16 years or greater than 
80 years of age, serum PTH level was greater than 1000nglL, serum 
phosphate was greater than 2.5mmoVL or serum corrected calcium was 
greater than 2.6 mmoVL. 
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5.3.2 Experimental Protocol 
Patients were washed out from previous treatment for a four week 
period. This includes both vitamin 0 and oral phosphate binders. 
Patients were removed from the study and restarted on their previous 
treatment if their serum phosphate level exceeded 3 mmoVL. At the end 
of the washout period initial bone biopsy with proline incorporation was 
performed and blood sampled for 1-84 PTH allowing for comparison of 
results with age matched non-CKD control data from previous studies 
carried out by Professor Rennie's group (143,144). 
For the second phase of study patients were allocated to receive either 
Calcium Carbonate or Sevelamer by the investigator to achieve the 
same degree of phosphate control (1.2-1.8 mmoVL). Doses were titrated 
over 4 weeks to achieve serum phosphorous level of 1.2-1.8 mmol/L and 
then maintained at this level for a further 8 weeks before undergoing a 
second bone biopsy to determine bone collagen formation rate, in 
concert with repeat assay of serum PTH. Vitamin 0 was not utilised to 
avoid confounding effects of vitamin 0 on osteoblastic function. At the 
end of the study patients were returned to their original pre study 
medication. 
5.3.3 Protocol for Bone Biopsy 
Subjects were biopsied on a non-dialysis day having been fasted from 8 
p.m. the day before the study to reduce any effect of dietary protein on 
CFR. A detailed description of the biopsy protocol can be found in 
Chapter 3. 
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5.3.4 Sample Analysis 
Collagen synthesis measured as incorporation of tracer proline into 
bone protein hydroxyproline 
• Sequential extraction of collagen from bone. 
50 mg of bone was ground to a fine powder under liquid N2. and 
subjected to differential extraction with 0.15M NaCI-O.05 M Tris - 0.2 M 
EDT A (pH 7.5), 0.5 M acetic acid, and pepsin-0.5 M acetic acid and then 
precipitated with 5 M NaCI Purified collagen was collected by 
centrifugation at 50,000 rpm for 45 min, dissolved in 0.5 M acetic acid 
and stored at -20°C until analysis. 
• Gas chromatography-combustion-isotope ratio mass spectrometry 
(GC-C-IRMS) 
Isolated collagen was hydrolysed (6 M HCI, 120°C, 15 h), and the free 
amino acids purified using cation exchange chromatography (Dowex 
50WX8-2oo, Sigma Ltd, Poole, UK). The proline and hydroxyproline 
were derivatized as their N-acetyl-n-propyl esters (NAP) and analysed by 
capillary GC-C-IRMS (Delta- plus XL, Thermofinnigan, Hemel 
Hempstead, UK) 
• Gas Chromatographic-Mass Spectrometric (GC-MS) Analysis. 
Plasma and tissue free proline, were extracted as previously described. 
Proline was prepared as the tert-butyldimethylsilyl (t-BDMS) derivative 
before analysis (MD800 GC-MS [Thermofinnigan, Hemel Hempstead, 
UK]). 
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Measurement of transcription and translation of osteoblast gene 
products 
• RNA preparation and cDNA synthesis 
Total RNA was extracted from bone for RT-PCR, the feasibility of which 
has been successfully proven by a number of recent studies (145). Bone 
(50-75 mg) was powdered under liquid N2 and transferred to Qiagen 
RNeasy spin columns, as per the manufacturer's instructions, with 
Proteinase KI DNase digestion steps. RNA concentration and purity 
were determined by measuring the fluorescence ratio at 260 and 280 
nM. Total RNA was reverse-transcribed into cDNA into 50 ml using PE 
Applied Biosystems Taqman Reverse transcription reagents as per 
manufacturer's instructions. 1ml, i.e -1-4 I..Ig of input RNA were used in 
subsequent Taqman analysis. 
• Taqman quantitative real-time PCR analysis 
Sequence-specific primers and probes for Taqman quantitative PCR 
analysiS of mRNA expression will be designed for our RNA targets using 
the Perkin Elmer Applied Biosystems Primer Express software, 
according to the manufacturer's protocol. Each assay is designed such 
that the probe spans an intron/exon boundary to minimize the possibility 
of co-amplifying genomic DNA PCR (1 x (50°C, 2 min, 95°C, 10 min), 40 
x (92°C, 15 sec, 60°C, 1 min» is performed in the presence of 0.6 x 
Taqman Universal PCR Master Mix (PE Applied Biosystems), forward 
and reverse primers and a sequence-specific fluorescent probe. To 
ensure specificity of amplification, all primer sequences include a 
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minimum of 2 unique nucleotides at the 3' end. Optimal probe! primer 
concentrations will be determined for each assay. A panel of cDNA 
clones, representative of each gene of interest, will be used to confirm 
specificity of amplification. Real-time PCR will be performed using an 
ABI Prism 7700 Sequence Detector (''Taqman"), in which fluorescence 
output, measured as cycle threshold (Ct) , is proportional to input cDNA 
concentration. Ct values in the range 35-40 units will be interpreted as 
being at the limit of Taqman detection and therefore will not be 
quantitated. Input [cDNA] will be normalised to bone GAPDH ribosomal 
RNA using PE Applied Biosystems Ribosomal RNA control reagents. 
Parathyroid Hormone Assays 
Intact I 1-84 Parathyroid Hormone was measured using the DPC 
Immulite 2000 PTH assay by staff within the department of biochemistry 
at Royal Derby hospital. Reportable range 3.0-2500 nglL. Normal 
reference range 11-67 ng/L (Serum). 
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5.4 RESULTS 
Patients 
We initially recruited 9 male patients from the chronic haemodialysis 
programme at Royal Derby Hospital. Demographic data is shown in 
Table 8 below. 
Subject I Age HD Cause of PTH cCalcium Phosphate 
I 
i (years) Vintage ERF (nglL) (mmoVL) I (mmoVL) 
(months) I I I I I 
I 1 66 49 Renovascular 107 1 2.50 1 2.50 
I Id- I I I I I 
12 48 12 ! Diabetic 
1
524 2.24 1.88 
I 
I 
I 
I I nephropathy I ! 
3 69 24 APKD 1 31 2.59 i 1.37 
I 
I I 
i I 
i I I I 
4 68 10 I Diabetic 
1
53 2.50 I 1.44 
I I nephropathy I I I I 
5 77 42 APKD 
1
156 2.31 
1
2
.
04 
I I 
6 68 19 ! APKD 383 
1
2
.
34 \1.51 I 
I I I 
17 63 
i 28 I Diabetic 
1
139 1 2.33 11.36 
I I I ! nephropathy I 
8 i 75 \69 Obstructive 69 i 2.50 1.90 I 
uropathy i I I 
1
9 i 63 19 Amyloidosis ' 311 1 2.32 I 1.91 I 
I 
I 
I I 
I i 1 I 
Table 8. Demographic data at recruitment visit 
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I 
I 
I 
I 
1 
I 
I 
I 
I 
Collagen Synthesis Rate measured as Fractional Synthetic Rate 
(FSR) following washout period 
None of the 9 subjects recruited developed a serum phosphate greater 
than 3mmoI/L during the washout phase and so were eligible to remain 
within the study and proceeded to initial bone biopsy. FSR for collagen 
were determined. These data are presented alongside measured iPTH 
level recorded for each subject at time of biopsy in Table 9. There were 
no significant differences in serum phosphate or calcium levels between 
patients (2.1 ±O.29, 2.29±O.13 respectively). FSR (O/Olhr) was higher in 
haemodialysis patients than matched non uraemic controls (O.069±O.015 
versus O.054±O.OO6, p=O.013) (143,144). Circulating iPTH levels did not 
correlate with bone collagen FSR (r= -0.44, p=0.23). 
Subject 
1 
2 
3 
!6 
I 
FSR (%/hr) 
0.101 
0.073 
i 0.070 
1
0
.
063 
1
0
.
057 
1
0
.
064 
1
0
.
076 
10.050 
I 
iPTH (nglL) 
49 
201 
i 52 
1636 
I 
Table 9. FSR collagen versus iPTH level in prevalent male haemodialysis patients 
following 4 week washout of vitamin 0 and phosphate binder medication. 
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I 
I 
I 
I 
I 
Phosphate normalisation with calcichew/seve/amer and collagen 
synthesis rate 
Unfortunately two patients withdrew from the study following the washout 
period and initial biopsy. Of those remaining 4 were allocated to receive 
sevelamer and 3 to receive calcichew to achieve target phosphate 
control. Target phosphate level (1.2-1.8 mmollL) was achieved and 
maintained in all subjects. Table 10 shows mean phosphate and mean 
corrected calcium over an 8 week period, phosphate binder dosage and 
iPTH at the time of repeat bone biopsy. 
Sevelamer 
Subject I Serum Phosphate I Binder Dose , Serum cCalcium iPTH 
I 
I (mmoVl) I (g) I (mmoVL) (ngIL) 
1
3 1 1.55±0.22 1 4.00 2.52%0.17 57 
I I 
14 1 1.54:1:0.25 1 7.20 2.50:1:0.13 487 I I 
I I I I 
!7 I 1.34:1:0.21 1 3.20 2.41:1:0.06 i66 i I 
19 1.31:1:0.24 2.40 2.34:1:0.05 i 705 
I 
Calcichew 
I Subject I Serum Phosphate I Binder Dose (g) I Serum cCalcium iPTH 
I I (mmoVl) I J (mmoVl) (nglL) 
1
5 i 1.33:1:0.23 6.25 I 2.47:1:0.21 202 
i i 
1
6 I 1.69±0.12 1 8.75 1 2.35:1:0.12 217 
! ! i 
18 j 1.34:1:0.15 15.00 2.21:1:0.24 354 
I I 
Table 10. Mean serum phosphate, cCalcium, iPTH and binder dose by subject 
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Following 8 weeks of phosphate optimisation we attempted to reassess 
bone collagen formation rate using 15N labelled proline to avoid any 
effect of remnant 13C given at the time of the initial biopsy on 
determination of fractional synthetic rate. 
Unfortunately data obtained using 15N labelled proline demonstrated 
higher levels within skin at baseline than within bone 120 minutes 
following dose of labelled proline. This meant that we were unable to 
calculate a synthesis rate. We repeated the analysis two further 
occasions and obtained very similar results. At this point, given the 
invasive nature of the process we felt that it was not appropriate to 
continue recruitment until we could explain this anomaly and the study 
was closed. 
Transcription and translation of osteoblast gene products 
We were successful in demonstrating expression of RANKL and OPG in 
4 subjects at baseline using the described techniques. However due to 
the problems with attempts to determine collagen formation rate and 
small samples obtained at bone biopsy we had insufficient bone to 
perform repeat testing post phosphate optimisation. We were therefore 
unable to determine the effect of calcium and non-calcium containing 
phosphate binding medication on gene expression of these osteotropic 
factors. 
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5.5 DISCUSSION 
The inability of the skeleton to adequately buffer the internal milieu and 
maintain its essential role in homeostasis has far reaching 
consequences in subjects with CKD. Given the interdependence of 
calcium, phosphate, vitamin 0 and PTH status, no singJe intervention is 
usually sufficient to completely restore abnormalities in their metabolism 
in the setting of progressive uraemia. PTH is the major determinant of 
bone formation and turnover in patients with CKD (146). Accordingly, 
measurements of PTH levels in serum or plasma have been used for 
many years as a non-invasive biochemical method for diagnosis and 
monitoring progression and response to therapeutic intervention. 
The initial data obtained from the study for basal collagen synthesis rate 
in our subject group suggests that there is no correlation between 
measured iPTH levels and bone turnover as measured by FSR. This 
would be in agreement with previous published data (141, 142). 
Measured iPTH at the time of bone biopsy ranged from 44ng/L to 
636nglL. Interestingly, the highest recorded level for iPTH (636ng/L) was 
associated with the lowest measured FSR (O.05%/hr). Characteristic 
histomorphornetric findings at bone biopsy in the setting of an elevation 
in PTH of this level would typically be consistent with increased bone 
turnover. 
Disappointingly, the raw data obtained following phosphate normalisation 
utilising 15N labelled proline did not allow us to derive FSR in our 
subjects. The initial levels of 15N detected in baseline skin samples was 
far in excess of those obtained from bone two hours after flooding dose 
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of tracer. A potential reason for this is that collagen kinetics within skin in 
the uraemic setting might differ from those in non-uraemic subjects and 
may be associated with greater recycling of proline. It is unclear at this 
time why this only appears to have been an issue relating to 15N 
detection. However, in this setting it did mean that skin could not provide 
a surrogate reflection of collagen synthesis within bone and therefore 
could not be used to estimate a basal rate within bone. The 
investigational technique would therefore require revision before it is 
utilised again in the uraemic setting. One simple solution would be to 
replace the initial skin biopsy with bone biopsy. This obviously increases 
the invasive nature of the procedure and would lose some of the 
intended benefit. The difficulties experienced with the technique had 
necessitated repeat analysis of samples and as a direct consequence of 
this we had insufficient bone to perform PeR and establish expression· of 
gene markers of bone turnover in many cases. In the instances where 
we were left with (theoretically) sufficient bone mass, it became apparent 
that the relative acellularity of bone meant that larger quantities would 
actually be required in order to extract sufficient bone RNA to go on to 
perform analysis of expression of gene products. Using stored samples 
from a separate study which had involved collagen formation rates 
relating to hip fracture, where entire femoral necklhead was removed as 
part of total hip replacement surgery we established that repeated, 
reliable extraction of RNA was possible in samples of ~ 1 0 0 m g . .
There are multiple potential markers for bone turnover. The process of 
osteoclastic bone resorption results in the liberation of bone mineral and 
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osteoid, which is subsequently metabolised to peptides that can be 
measured in serum and urine. Examples include urinary N-telopeptide 
(NTx) and serum C-telopeptide (CTx). Similarly, osteoid formation leads 
to the production of proteins such as osteocalcin and by-products of 
collagen synthesis that may also be measured in serum. These 
biomarkers have some utility in certain clinical settings such as 
osteoporosis but there is a paucity of data regarding use in CKD-MBD. 
Assay variability and poor standardisation have also limited their 
usefulness in the clinical setting (147). In addition, biological variability 
due to a large number of physiological, pathological, circadian and 
dietetic factors must also be considered when interpreting these results 
(148,149). 
The gold standard for diagnosis of bone disease remains 
histomorphometric assessment of bone biopsy. Despite the limitations, 
iPTH remains the most utilised marker for the assessment of bone status 
in CKO-MBD. Our limited data supports previously established limitations 
in its usefulness. CKD progresses to a multisystem disorder that leads to 
widespread organ damage. Disturbances in bone and mineral 
metabolism are common and biochemical and hormonal derangements 
apparent early. Timely, optimal management is essential to maintain the 
homeostatic role of the skeleton and thus minimise cardiovascular 
damage in our patient group. To date there is no single serological 
marker that adequately reflects bone activity in the uraemic setting. This 
is a highly interesting and complex area that requires ongoing research. 
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6 MYOCARDIAL CONTRACTILE 
FUNCTION & INTRADIAL YTIC 
HYPOTENSION 
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6.1 Introduction 
Despite continued advances in haemodialysis technology, intradialytic 
hypotension (IDH) remains highly prevalent in the chronic haemodialysis 
population. IDH has been reported in about 30% of sessions (75-77) and 
is associated with high rates of morbidity and mortality (78). The 
pathophysiology of IDH is multifactorial but involves inadequate 
compensatory mechanisms to hypovolaemia induced by ultrafiltration. 
These include a decrease in venous capacitance, increase in total 
peripheral resistance and increased cardiac output (75). Failure of any of 
these mechanisms predisposes patients to IDH. However, controversy 
exists as to which component is the most important in its development. 
Additionally, there is increasing evidence implicating IDH in the 
pathophysiology of 'uraemic cardiomyopathy'. IDH increases the risk of 
myocardial hypoperfusion leading to segmental ischaemia inducing 
segmental left ventricular dysfunction (73), a process known as 
myocardial stunning (74). Myocardial stunning is cumulative and leads 
to irreversible left ventricular dysfunction in ischaemic heart disease 
(150, 151, 152). 
Pharmacological stress is in routine use in the diagnosis of ischaemic 
heart disease, by exposing areas of ventricular dysfunction during 
echocardiography. Dobutamine at low dose (:S10IJglkg/min) acts 
predominantly as an inotrope and at higher doses exerts a more 
chronotropic effect. It has been shown to be safe, feasible and effective 
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in prognostic assessment in the general population (153). It has been 
shown to be safe in haemoclialysis patients. Dobutamine stress echo has 
been reported to demonstrate differences in cardiac output, stroke index 
and SSP between hypotension-prone and non hypotension-prone 
patients (154). 
As the overall age of the dialysis population increases so does the 
burden of cardiovascular disease. This further increases the propensity 
of this population to IDH. The ability to identify patients likely to be at risk 
of IDH would therefore allow us to target these patients with superior 
dialysis techniques associated with less risk of IDH, prior to delivering a 
period of potentially harmfullDH prone standard HD. 
6.2 Aims 
The aim of our study was to perform non-invasive measurement of 
cardiovascular parameters in a group of chronic haemoclialysis patients 
undergoing pharmacological stress, in place of dialysis induced cardiac 
stress, allowing us to ascertain the dominant functional abnormalities 
that might predispose patients to IDH. 
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6.3 Methods 
6.3.1 Patients 
Ten non-diabetic chronic HD patients were recruited for the study. Five 
were classified as having been hypotension prone (HP) on dialysis and 
five acting as controls were known to be stable on dialysis (hypotension 
resistant) (HR). IDH was defined as symptoms of hypotension during HD 
for at least one third of dialysis sessions for greater than one year, plus 
either systolic blood pressure (SBP) less than 100 mmHg, or SBP 
reduced by at least 25%. Three patients were female and the patients in 
the two groups were well matched for age, dialysis vintage and baseline 
haemodynamics. None of the patients had a history of overt ischaemic, 
or Significant valvular heart disease. Patients had echocardiography 
prior to the study. All patients were dialysing three times a week with 
conventional HD. Patients were excluded from the study if they were 
taking vasoactive medication, had a history of cardiac arrhythmias or 
ischaemic heart disease/acute coronary syndrome. 
All patients gave written informed consent. Ethical approval for the 
project was granted by Derbyshire Local Research Ethics Committee. 
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6.3.2 Study protocol 
Dobutamine-atropine stress (DAS) pulse wave analysis was performed 
in all patients one day following a HD session to reduce the likelihood of 
significant post dialysis hypovolaemia. All patients underwent clinical 
examination prior to commencing DAS and were subjectively deemed to 
be euvolaemic. Patients were studied in a fasted state and usual 
medications were continued. Non-invasive haemodynamic monitoring 
was performed throughout the study with the use of the F i n o m e t e ~ ~
(Finapres Medical Systems, Arnhem, The Netherlands). Baseline 
haemodynamic parameters were obtained for each patient with 10 
minutes of monitoring prior to the start of the Dobutamine infusion. The 
finger cuff was left in place for the duration of the study on the non-fistula 
arm. Each patient had an initial 12 lead ECG followed by continuous 
ECG monitoring. 
Primary endpoints were change in blood pressure (BP) from baseline 
and percentage change in CO, Stroke Volume (SV) and Total Peripheral 
Resistance (TPR), in response to Dobutamine-atropine stress. 
Secondary endpoints were change in heart rate and BRS. 
6.3.3 Dobutamine-atropine stress 
DAS was performed after initial baseline haemodynamic monitoring. 
Dobutamine was infused intravenously via a peripheral cannula following 
the same protocot in each patient. Dobutamine infusion was initiated at 
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5 ~ g l k g / m i n n for 5 minutes followed by 10",glkg/min for 5 minutes. This 
was defined as the "'ow dose" period. Following this the Dobutamine was 
increased by 10lJQlkglmin every 3 minutes, to a maximum of 
40",glkglmin (high-dose), unless a test endpoint was reached. If a test 
end-point was not reached despite maximum dose Dobutamine then 
atropine was added intravenously to a maximum of 2mg. 
Test end-points were 1) achieved target heart rate (220-age), 2) peak 
dose of DobutamineJAtropine 3) chest pain or ECG evidence of cardiac 
ischaemia, 4) severe hyper- or hypotension (systolic blood pressure 
>220mmHg or <90mmHg, diastolic blood pressure >110 mmHg or 
<30mmHg), and 5) intolerable symptoms. 
6.3.4 Finometer 
The Finometer allows continuous non-invasive beat-to-beat 
haemodynamic monitoring. This technology uses pulse-wave analysis at 
the digital artery together with Modelflow™ algorithms to reconstruct a 
central aortic waveform (103). This provides beat-to-beat estimates of 
cardiac output, stroke volume and peripheral resistance as well as BP 
and heart rate measurements. The Finometer is useful at tracking 
relative change but needs calibration against another measurement for 
absolute values (155). In our centre we have widely utilised the 
Finometer to track change from baseline of haemodynamic variables in 
CKD patients. These have been validated against changes seen on 
echocardiography and have shown a strong correlation between 
percentage change in SV measured by the two techniques (156). As we 
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were interested in changes in haemodynamics, these are presented as 
percentage change from baseline except for BP, which is calibrated 
against brachial readings, where absolute values are shown (106). 
BRS was calculated from the regression slope between interbeat interval 
and beat to beat changes in blood pressure. Multiple consecutive 
changes in interbeat interval in the same direction are required before a 
phase shift calculation (incorporated into the software) is performed. 
BRS measured in this way gives a compound indication of the activity of 
the autonomic nervous system (112,157). 
6.3.5 Statistical analysis 
Results are expressed as the mean ± SE unless otherwise stated. Blood 
pressure and haemodynamic data with increasing Dobutamine dose 
were analysed with a one-way ANOVA (repeated measures) with 
Dunnetts test to compare results with control data before the start of 
Dobutamine infusion. 
Unpaired t tests were used to compare averages between groups in the 
case of parametric data or the Mann-Whitney U test for non-parametric 
data. For all tests, a P value of less than 0.05 was judged to be 
significant (ns=not significant). 
All data were analysed using GraphPad Prism version 4.00 for Windows 
(Graph Pad Software, San Diego, CA). 
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6.4 Results 
Number 5 5 ns 
Age 61 .2± 6.0 65.2± 4.2 ns 
(41-77) (54-75) 
Sex malelfemale 3/2 4/1 ns 
Haemodialysis 2.2±0.5 5.3±1 .5 ns 
vintage- years (1 -3) (1 -10) 
Hematocrit 0.4 ± 0.01 0.4 ± 0.02 ns 
LVMI 64.3 ± 20.3 62.8 ± 15.5 ns 
Hemodynamics 
SBP, mmHg ns 
123.1 ±5.8 120.8 ± 8.5 
MAP, mmHg 91 .5 ± 5.4 88.5 ± 4.7 ns 
DBP, mmHg 71 .5 ± 5.5 68.2 ± 4.8 ns 
HR, bpm 78.6± 3.9 85.7 ± 6.1 ns 
BRS, ms/mmHg 3.6± 0.6 2.1± 0.7 ns 
Table 11 Baseline clinical characteristics of hypotension resistant (HR) and 
hypotension prone (HP) patients. Abbreviation : LVMI, left ventricular mass index. 
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Baseline patient information is shown in table 11. DAS pulse-wave 
analysis was successfully carried out in all 10 patients. All patients 
required full dose Dobutamine and atropine as per the protocol to 
achieve target heart rate. Target heart rate was achieved in all patients 
without symptomatic hypotension, ischaemic ECG changes or other 
significant side effects. 
Blood pressure response to DAS 
After initiation of Dobutamine in HR patients there was no Significant 
change in any of the measures of BP. Mean arterial pressure (MAP) 
increased from a baseline of 91.5 ± 5.4 mmHg to 91.8 ± 4.6 mmHg 
(p=ns) at peak heart rate after atropine. SBP fell from a baseline of 123.1 
± 5.8 mmHg to 121.2 ± 3.5 mmHg (p=ns) at peak heart rate and DBP 
increased from 71.5 ± 5.5 mmHg to 78.3 ± 4.6 mmHg (p=ns) after 
atropine. However, in the HP group there was a significant change in 
blood pressure during Oobutamine-atropine stress. SBP at baseline of 
120.8 ± 8.5 mmHg fell to 95.9 ± 9.4 mmHg (p<0.001) at peak heart rate, 
MAP fell from 88.5 ± 4.7 mmHg to 74.9 ± 6.4 mmHg (p<0.001)and DBP 
from 68.2 ± 4.8 mmHg to 62.2 ± 5.7 mmHg (p=ns) at maximum heart 
rate. 
Comparing HR to HP, the HR patients exhibited a mean SSP of 126.9 ± 
2.9 mmHg, mean DSP was 75.52 ± 1.6 mmHg and mean MAP was 
93.05 ± 0.7mmHg for the duration of the study after initiation of DAS. In 
the group defined as HP, all BP parameters were lower, mean SSP was 
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109.5 ± 8.1mmHg (p=ns), mean DBP was 65.26 ± 2 mmHg (p<0.05) and 
mean MAP was 81.27 ± 4.1 mmHg (p<0.05). BP data are summarised in 
figure 4. 
Hemodynamic response to DAS 
Heart rate increased significantly with increasing Dobutamine-atropine 
dose within each group. In the HR group baseline heart rate increased 
from 78.6 ± 3.9 beats per minute (bpm) to 147.3 ± 6.1 bpm (p < 0.001). 
In the HP patients baseline heart rate increased from 85.7 ± 6.1 bpm to 
147 ± 3.2 bpm (p < 0.001). There were no significant differences in 
mean heart rates between the two groups throughout the study, HR 
111.7 ± 19.1 bpm versus a mean heart rate in the HP patients of 118.5 ± 
15.9 (p=ns). 
SV declined in both groups throughout the study. In the HR patients SV 
fell by 28.2 ± 3.6% from baseline (p<0.001) and in the HP patients SV 
decreased by 41.2 ± 6.1% from baseline (p<0.001). In a comparison 
between the groups after initiation of Dobutamine in the HR patients the 
mean SV was 8 ± 10.3 % below baseline and in the HP the mean SV 
was 24.8 ± 11.3 below baseline (p=ns). 
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Figure 4. 
Blood pressure response in HR and HP patients to Dobutamine-atropine stress 
expressed as absolute change. MAP and DBP was significantly higher in HR patients 
for duration of the study *p<O.05. 
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Figure 5. Systemic haemodynamics during Dobutamine-atropine stress in HR and HP 
patients. CO was significantly greater in HR patients *p<O.05. 
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I 
Table 12. Haemodynamic response to Dobutamine-atropine stress in hypotension resistant (HR) and hypotension prone (HP) patients . 
. 
p<O.001 versus baseline by ANOVA 
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In response to DAS in the HR group CO increased by 33.4 ± 6% above 
baseline (p<0.001) but only by 0.5 ± 7.9 % from baseline in the HP group 
(p=ns). During DAS in the HR patients the mean change in CO was +24.7 ± 
7.5 % as compared to a mean change of - 0.2 ± 2.6 % in the HP (p<0.05). 
TPR declined in both groups during the protocol. However, TPR declined to 
a lesser extent in the HP group. TPR fell by 22.7 ± 2.9% from baseline 
(p<O.001) in the HR but only by 10.3 ± 6.8% in the HP group (p=ns). The 
mean TPR for the entire study in the HR was - 16.7 ± 5.5 % compared with 
a mean of - 5.1 ± 2.6 % in the HP patients (p=ns). Haemodynamic data are 
summarised in figure 5 and table 12. 
There were no significant differences in BRS between groups at baseline. 
BRS increased from baseline with low dose DAS (p=ns) but then decreased 
with increasing DAS stress. In the HP group BRS decreased with 
progressively higher levels of pharmacological stress. There was a trend for 
mean BRS to be higher in HR patients throughout, (*p<0.05 with low and 
high dose dobutamine). BRS data are summarised in table 13. 
Low dose dobutamine 4.8± 0.4 
High dose dobutamine 3.2± 0.8 1.3± 0.3* 
Atropine 2.4± 0.7 1.3± 0.8 
* p<0.05 
Table 13. BRS response to Dobutamine-atropine stress in hypotension resistant (HR) 
and hypotension prone (HP) patients 
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6.5 Discussion 
This is the first study in which Dobutamine-atropine stress in association 
with non-invasive pulse wave analysis has been used to differentiate 
between HR and HP patients in terms of their haemodynamic response, 
with a significant fall in MAP in the HP group. 
Dobutamine stress is commonly used to investigate ischaemic heart 
disease by exposing new areas of ventricular dysfunction seen on 
echocardiography. Failure to increase CO was primarily due to a greater fall 
in SV seen in the HP patients as both groups increased their heart rate by 
similar amounts. This is in keeping with the findings by Poldermans et al 
who in their study using Dobutamine stress echocardiography were able to 
demonstrate that patients defined as hypotension prone were unable to 
increase cardiac index and that this was primarily due to a failure to 
increase stroke index in response to Dobutamine (154). This they defined 
as an impairment of myocardial contractility in the HP group. The 
impairment of myocardial contractile reserve as a cause of IDH is also 
supported by work by Nette (158). In the study by Boon et al in which they 
monitored haemodynamics during uncomplicated haemodialysis, a greater 
fall in SV was also responsible for the decline in CO seen in their patients in 
whom systoliC blood pressure fell during haemodialysis (159). However, 
impairment in myocardial contractility was not thought to be relevant to the 
pathogenesiS of IDH in the study by Ie EH et al (160). 
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Likewise, it was this inability to increase CO that was responsible for the fall 
in BP seen in the HP patients, as there was no Significant difference in the 
response of TPR, which fell in both groups, but to a lesser extent in the HP 
group. 
The difference in stroke volume response could be explained by differences 
in preload. However, in our study, to counter the influence volume status 
has on SV we studied patients on a day preceding their next dialysis 
session and examined them to ensure they were in a euvolaemic state. This 
ensured that the haemodynamic response to DAS that we observed was 
independent of the volume changes during ultrafiltration that have been 
impHcated in dialysis induced hypotension. 
Left ventricular hypertrophy (LVH) is a common finding amongst 
haemodialysis patients. It has been postulated that L VH and the subsequent 
diastolic dysfunction may be important in the aetiology of IDH. In our study, 
echocardiography pre study did not demonstrate a Significant difference in 
left ventricular mass index. Therefore we suggest that LVH as a cause of 
diastolic dysfunction was not an important factor in differentiating the 
development of hypotension in these patients. 
We exctuded patients with a history of ischaemic heart disease and no 
patients experienced symptoms or had ECG changes that would be 
compatible with overt ischaemia during the study. It therefore seems 
unlikely that impairment of myocardial contractility could be explained by 
ctassical epicardial coronary artery disease alone in our patients. However, 
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just as dialysis has been suggested to induce subclinical ischaemia and 
myocardial stunning (150) we postulate that this process (but induced by 
DAS) may also be responsible for the inability to increase stroke volume, 
which was seen more in the HP prone patients in our study. 
Repeated episodes of myocardial stunning may put patients at increased 
risk of dialysis induced hypotension and lead to left ventricular dysfunction 
associated with increased mortality. Interestingly, despite maximal doses of 
Dobutamine in both groups we saw falls in stroke volume, which in part was 
due to decreased cardiac filling time with increasing heart rate. In patients 
with non-ischaemic cardiomyopathy this inability to increase left ventricular 
ejection fraction has been shown to be a predictor of survival(161). 
Autonomic dysfunction has also been considered to be an important factor 
in the propensity to IDH. Baroreflex sensitivity a marker of autonomic 
nervous system function was measured in our patients. The trend to 
decreasing BRS in the HP group is consistent with involvement of 
autonomic dysfunction in the development of IDH and is compatible with 
work by other groups (89,162). 
Our study does have some potential weaknesses. We have only used small 
numbers of patients. The study should therefore be replicated with 
increased numbers. Furthermore, it would be interesting to monitor the 
same cohort of patients whilst on HD to see if the changes to 
haemodynamics seen during DAS are matched during HD. We do not have 
any direct measure of vascular function (in particular arterial stiffness), 
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which will also impact on response to pharmacological stress. However, this 
study has demonstrated that this method is not only applicable to this 
patient group but is also not associated with adverse effects. 
In conclusion, this study demonstrates that Dobutamine-atropine stress in 
conjunction with non-invasive pulse wave analysis can be used to 
distinguish between HP and HR patients. It also provides an insight into the 
potential underlying pathophysiology responsible for the development of 
IDH. Intradialytic haemodynamic instability appears to be important in the 
development of recurrent cardiac injury. Worsening myocardial contractile 
reserve, predisposing to further instability, provides a 'vicious cycle' of 
escalating risk and harm within a single pathophysiological process. 
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7 PROSPECTIVE STUDY OF THE DETERMINANTS OF 
SECONDARY DEPLETION OF CARNITINE AND THE 
SKELETAL AND CARDIAC FUNCTIONAL EFFECTS 
OF L-CARNITINE SUPPLEMENTATION IN INCIDENT 
CHRONIC HAEMODIALYSIS PATIENTS 
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7.1 Introduction 
Camitine, as a substrate for camitine palmitoyltransferase 1 (CPT1). plays 
an essential role in the translocation of intracellular long-chain fatty acyl 
groups into the mitochondrial matrix for subsequent ~ - o x i d a t i o n n (163.164). 
In addition. other functions of camitine include modulating concentration of 
fatty acids, scavenging toxic acyl groups and facilitating their transport out of 
mitochondria. Impairment of fatty acid metabolism and accumulation of acyl 
CoA are characteristic of renal failure. Camitine homeostasis in humans is 
maintained by endogenous camitine synthesis, dietary camitine intake, and 
efficient conservation of camitine by the kidney, in order to maintain a total 
body content of around 120 mmol (165). Humans obtain approximately 2 to 
12 ~ m o l · k g - 1 1 of camitine per day from dietary sources such as meat and 
dairy products, and up to 1.2 ~ m o l · k g - 1 · d - 1 1 by endogenous synthesis. 
Camitine biosynthesis occurs predominantly in the liver and kidney. Almost 
all of the camitine excreted during normal conditions occurs through the 
kidney (166), with more than 90% of filtered free camitine (FC) being 
reabsorbed (167). In contrast, tubular absorption of acylcarnitine is limited, 
resulting in clearance levels between 4 and 8 times that of free camitine, 
highlighting the role of camitine in removal of potentially toxic acyl groups 
(168). More than 95% of the body's total camitine (TC) store exists within 
skeletal muscle tissue (165) where one of its roles is to buffer excess acetyl 
groups from pyruvate oxidation, in a reaction catalysed by carnitine 
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Skeletal muscle TC content is known to be considerably reduced in ERF 
patients undergoing haemodialysis treatment. Haemodialysis vintage has 
been strongly correlated to the progression of TC depletion (169-172). 
However, despite 30 years of research in the area it remains unclear as to 
how and why this deficiency occurs. FC is freely filtered into the dialysate 
during a haemodialysis session and, as such, plasma TC concentration falls 
dramatically by up to 80% and is then replenished within a few hours of the 
cessation of HD (27,173,174). Thus, it has been suggested that FC is 
leached from tissue stores in order to maintain plasma TC concentration, 
resulting in the observed muscle TC deficiency (27,173). On the other hand, 
the calculated weekly TC loss (sum of weekly dialysate removal and urinary 
excretion) in HD patients (800 to 2300 IJmol) has been reported to be 
similar, if not lower than weekly urinary TC excretion in healthy controls 
(1500 to 2500 IJmol), leading to speculation that a reduction in dietary intake 
and/or endogenous synthesis of carnitine must cause muscle TC defiCiency 
(169,173-178). Indeed, the kidney is a major site of carnitine synthesis 
within the body, and one might expect that ERF could well reduce 
endogenous camitine synthesis. However, the above studies were 
conducted in patients who had been receiving HD treatment for more than 1 
year, and it has subsequently been reported that a Significant proportion of 
plasma TC depletion occurs within the first year of HD treatment, where 
muscle TC content is depleted by approximately 20% (172), suggesting that 
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intradialytic TC removal could be greater during the first year of HD 
treatment. 
Exercise tolerance is clearly impaired in ERF patients undergoing 
haemodialysis treatment. Values for peak oxygen uptake (V02peak) in HD 
patients in the literature are around 20 ml·min-1·kg-1 and are consistently 
lower than age-matched controls (170, 171,179). The aetiology of this 
impairment in exercise capacity is likely multi-factorial, with impaired 
skeletal muscle blood flow (180-182), oxygen conductance (183,184), 
metabolism (171.185,186), and strength (179, 187) being implicated. 
Interestingly, the progressive decline in skeletal muscle TC content in HD 
patients has been correlated with exercise capacity (171), and HD patients 
have greatly reduced CPT1 activity compared to age-matched controls 
(170). Furthermore, both oral and intravenous L-camitine supplementation 
have been reported to increase aerobic exercise capacity (29,188-190). 
muscle cross sectional area (29), muscle fibre diameter (30,191,192), and 
muscle strength (29). 
Lack of myocardial contractile reserve is an important determinant of the 
haemodynamic response to haemodialysis. In a population whose 
cardiovascular morbidity is already Significantly elevated this represents a 
Significant problem. It is well established that inherited systemic camitine 
deficiency causes cardiomyopathy (193). Patients improve dramatically with 
supplementation (194). Studies have also shown subnormal levels of FC in 
ischaemic heart disease and heart failure (195,196). Amelioration of 
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cardiac arrhythmias (27) and left ventricular ejection fraction (28) has been 
demonstrated in several studies following replacement therapy with L-
camitine in prevalent haemodialysis patients. Other risk factors associated 
with myocardial dysfunction found in prevalent haemodialysis patients such 
as lipid abnormalities, erythropoietin resistant anaemia and chronic 
inflammation may also be ameliorated with L- carnitine replacement (27, 
197). In 2003, the National Kidney Foundation of America recommended 
the intravenous administration of 2Omg.kg-1 L-carnitine three times a week 
for 9 to 12 months (198). This prescription was not validated and is perhaps 
excessive given that it is more than ten times the reported weekly TC 
excretion of ERF patients undergoing haemodialysis treatment. 
7.2 Aims 
1) To further investigate how skeletal muscle becomes TC deficient 
over the first year of HD. 
2) Determine whether the deficiency is associated with impaired 
exercise tolerance. 
3) Determine whether intravenous L-carnitine administration can 
prevent muscle TC depletion over the first year of HD treatment 
and any impairment in exercise capacity. 
4) To observe any differential effect on cardiac function in incident 
haemodialysis patients who receive either 10 mg·kg-1 L-carnitine 
thrice weekly post dialysis versus placebo. 
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7.3 Methods 
7.3.1 Subjects 
Seven ERF patients participated in the study, which was approved by the 
Southern Derbyshire Local Research Ethics Committee in accordance with 
the Declaration of Helsinki. Before taking part in the study, all patients gave 
their written informed consent to take part in the study and were aware that 
they were free to withdraw at any point. Potential patients were recruited 
from clinics at the Renal Medicine Unit at the Royal Derby Hospital if they 
had been diagnosed with ERF, had a creatinine clearance of s10 ml'min-1, 
and were suitable to begin haemodialysis treatment. ERF patients on 
anticoagulation therapy or suffering from thrombocytopaenia were excluded 
due to potential bleeding risks following muscle biopsy. Subjects with 
exercise induced angina or a concurrent medical problem meaning that they 
would be unable to perform a graduated exercise test, with a history of 
seizures, or evidence of significant malnutrition were not included in the 
study. Patients were allocated to receive 10 mg'kg-1 L-carnitine (n=4; Shire 
Pharmaceuticals Ltd, Hampshire, UK) intravenously following each HD 
session (i.e. 3 times per week), or the equivalent voJume of saline (n=3; 
control), over the first year of treatment. The demographic data of the 
patients and aetiology of ERF is presented in Table 14. Each subject had a 
baseline transthoracic echocardiogram prior to initiation of dialysis. These 
were carried out by cardiothoracic technicians at the Royal Derby Hospital. 
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7.3.2 Experimental protocol 
Each patient reported to the laboratory no more than 1 week before, and 6 
and 12 months after their first haemodialysis session, at the same time of 
day on each visit, and performed an incremental exercise tolerance test to 
volitional exhaustion. The incremental shuttle walking test is described in 
detail in Chapter 3. Isometric handgrip strength was measured using a 
dynamometer devised by Bassey at al. (100). 
7.3.3 Sample collection and analysis 
During each experimental visit, a muscle biopsy sample was obtained from 
each patients from the vastus lateralis, approximately 1 h after the exercise 
tests, using the percutaneous needle biopsy technique (101), and was snap 
frozen in liquid nitrogen less than 5 s after removal from the limb (see 
Chapter 3 for detailed description). These were performed by the 
investigator. The sample was subsequently freeze-dried at a later date and, 
after removal of visible blood and connective tissue, powdered and 
analyzed for free camitine, acetylcamitine, and long-chain acylcamitine 
content using a modified version of the radioenzymatic method of Cederblad 
et al. (199). Samples were processed by Dr Francis Stephens and 
laboratory staff from the Centre for Integrated Systems Biology at the 
University of Nottingham. Values were subsequently summed in order to 
calculate muscle total camitine content. In addition, plasma samples were 
obtained before and after the first dialysis session and before and after 
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haemodialysis sessions at 1, 3, 6, and 12 months. A 24-hour urine collection 
and a dialysate sample (from partial sampling of complete dialysate waste 
collection from a single 4h HD session) were also obtained at these time 
points. All of these samples were then stored at -SO°C and analyzed at a 
later date for free and total camitine concentration using the radioenzymatic 
assay described previously by Cederblad & Lindstedt (200). In addition, a 
post-HD dialysate sample was collected from 31 HD patients (age 62.1 ± 
2.7 y; body mass 71.4 ± 2.5 kg) who had been on dialysis treatment for 41.4 
± 4.3 months (range 12-95 months). All analysis of these samples was 
carried out by staff within the Centre for Integrated Systems biology, 
University of Nottingham. 
7.3.4 Haemodynamic Data Collection 
At the initial dialysis session and at 1, 6 and 12 month dialysis sessions 
when samples were collected for determination of carnitine levels, systemic 
haemodynamic function was assessed using a Finometer (TNO Biomedical 
Instruments, Amsterdam, The Netherlands). The Finometer allows 
continuous noninvasive beat-to-beat pulse wave analysis at the digital artery 
using a cuff placed on the index finger providing estimates of cardiac output, 
stroke volume and peripheral resistance in addition to blood pressure and 
heart rate measurements. These parameters were recorded over an entire 
haemodialysis session. Detailed methods can be reviewed in Chapter 3. 
Results are generally reported as change from baseline except for blood 
pressure recordings which are recorded as absolute values. 
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7.3.5 Statistical analysis 
Where numbers permitted, a two-way ANOVA (time and treatment effects; 
GraphPad Prism 4.02, GraphPad Software Inc, CA) was performed to 
identify differences in muscle, plasma, urine, and dialysate carnitine content, 
walking distance and handgrip strength and intradialytic mean arterial 
pressure, heart rate and percentage change in stroke volume. When a 
significant main effect was detected, data were further analysed with 
Studenfs t tests using the Bonferroni correction. Otherwise, time effects 
were determined using one-way ANOVA or Student's paired ttests. 
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7.4 Results 
Patients 
Unfortunately two of the patients in the control group dropped out of the 
study after 6 months, 1 of whom volunteered to return for the exercise tests. 
Other demographic data are shown in Table 14. 
Subject Group Age Weight Gender Aetiology Co-morbidities Medication 
CS 
SO 
VM 
W 
GL 
KD 
OP 
(years) (kg) 
Control 61 66 Female GN IOH Ca2+ blocker; ~ I o c k e r ; ;
diuretic; aspirin; statin 
Control 40 90 Male ON Hypertension ACEi; aspirin; statin 
Control 69 85 Male GN IOH ACEi; Ca2+ blocker; 
diuretic; statin; phos binder 
Camitine 76 69 Male Other Ca2+ blocker; B-blocker; 
diuretic; a-blocker; aspirin; 
statin; phos binder 
Camitine 62 92 Male APKO HypertenSion ACEi; ea2+ blocker; phos 
binder 
Camitine 44 83 Male APKO HypertenSion ACEi; a-blocker 
Camitine 79 81 Male ON IOH Ca2+ blocker; diuretic; a-
blocker; aspirin; statin; 
phos binder 
Table 14. Subject demographic data, aetiology of ERF, co-morbidities, and medication 
prior to the start of the study. GN, glomerulonephritis; ON, diabetic nephropathy; APKD, 
adult polycystic kidney disease; IDH, intradialytic hypotension. 
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Plasma camitine 
Pre-HD session plasma TC concentration (Figure 6A) declined over the first 
6 months of HD treatment in the 3 control patients from a mean of 65.1 ± 
9.9 to 57.3 ± 8.8 Jjmol·r1, and over 12 months in one patient (47.3 to 44.9 
IJmol·r1). (Plasma TC normal reference range 34-78 IJmoH-1). In contrast, 
from a similar basal value of 79.1 ± 16.3 IJmol·r1, the Lv. administration of 
10 mg·kg-1 L-camitine to 4 patients following every HD session increased 
plasma TC concentration to 149.3 ± 2.4 IJmol·r1 after 1 month and then 
gradually increased to 250.2 ± 74.6 IJmoH-1 after 12 months, such that pre-
HD plasma TC concentration was higher than the control group throughout 
the 12 months of HD treatment. The pre-HD plasma acyl to free camitine 
ratio remained similar and constant in both control and camitine patients 
after 6 (0.6 ± 0.3 and 0.3 ± 0.2 IJmol·r1 to 0.4 ± 0.1 and 0.4 ± 0.3 IJmol·r1) 
and 12 (0.5 (1 subject) and 0.7 ± 0.4 IJmol·r\ respectively) months of HD 
treatment. (Plasma acyl to free camitine ratio normal reference range 0.1-
0.8 IJmol·r1). 
Plasma TC was depleted by a similar amount during the first HD session 
between the control and camitine patients such that the post-HD 
concentration was 27.6 ± 2.8 and 35.7 ± 5.6 IJmol·r1, respectively (Figure 
68). However, whereas post-HD plasma TC concentration declined 
gradually after 6 (17.2 ± 3.7) and 12 (8.8; 1 subject) months in the control 
patients, it remained constantly higher in the camitine patients (49.9 ± 8.3 
and 52.0 ± 18.9 JjmOI·r1 after 6 and 12 months, respectively). 
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Figure 6. Plasma TC concentration before (A) and after (8) each HD session over the 
course of the first year of HO treatment in ERF patients receiving placebo (white circles) 
or 10 mg·kg-1 i.v. L-camitine (black circles) following each HO session. 
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Urinary camitine 
Twenty-four hour urinary TC excretion before the first HD session was 
similar for the control and camitine patients (231.3 ± 80.0 vs. 377.3 ± 36.7 
~ m o l , , respectively; Figure 7A). However, whereas urinary TC excretion 
declined over the first year of HD treatment in the control patients (43.7 ± 
10.3 and 23.1 (1 patient) ~ m o l l for 6 and 12 months, respectively), 24 h 
urinary TC excretion increased to 716.4 ± 153.4 ~ m o l l after 1 month and 
remained constant for 12 months in the camitine patients. 
Dialysate camitine 
Dialysate TC content following the first· HD session was similar for the 
control and camitine patients (481.7 ± 14.5 vs. 575.3 ± 108.4 ~ m o l , ,
respectively; Figure 78). However, whereas dialytic TC removal appeared to 
decline over the first year of HD treatment in the control patients (1087.7 
and 453.2 ~ m o l l after 6 and 12 months (1 patient), respectively), dialytic TC 
removal increased to 3086.4 ± 7 41.1 ~ m o l l after 1 month and remained 
constant for 12 months. In addition, the mean dialytic TC removal during a 
single HD session in 31 control ERF patients with a dialysis vintage of 
greater than 12 months was 414.5 ± 35.3 ~ m o l · k g · 1 . . There was no 
correlation between camitine loss during a HD session and dialysis vintage 
(Figure 8). 
* The duration of the first HO session was 2 h whereas all HO sessions thereafter were 4 h. 
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Figure 7. Twenty-four hour urinary TC excretion (A) and dialytic TC removal (B) over the 
course of the first year of HD treatment in ERF patients receiving placebo (white circles) 
or 10 mg-kg-1 tv. l-camitine (black circles) following each HD session. 
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and number of months of receiving HD treatment in 31 ERF patients. 
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Muscle total camitine 
Skeletal muscle TC data are presented in Table 15 and illustrated in Figure 
9. Muscle TC content decreased by 3.6 :t 0.7 mmol'(kg dmr' (16%; P>0.05) 
after the first 6 months of HD treatment in the control group. Unfortunately, 
muscle biopsy samples were not obtained from two of the control patients 
after 12 months of HD treatment, although muscle TC appeared to decrease 
by a further 5% in one of the control patients. In contrast, there was no 
decline in muscle TC content following 6 or 12 months of HD treatment in 
the camitine group, which remained at a similar value to baseline (Fig. 9). 
Exercise tolerance 
Total walking distance during the exercise tolerance test (Table 15) before 
and after 6 months of the commencement of HD treatment was similar in 
the control and camitine patients. Over the first year of HD treatment total 
walking distance decreased in 2 of the control patients (by 30 and 60%) and 
2 of the camitine patients (by 20 and 40%), and increased in 2 of the 
camitine patients (by 110 and 190%). There was a weak correlation (,-2 = 
0.734; P = 0.06) between the change in muscle total camitine content over 
the first 12 months of HD treatment and the change in total walking distance 
(Fig. 10). 
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Table 15. Muscle total carnitine content. total walking distance during an incremental exercise test. and handgrip strength over the course of the 
first year of HO treatment in 3 ERF patients receiving placebo (control) or 10 mg·kg-1 i.v. l-carnitine (carnitine) following each HO session. 
Muscle total carnitine Walking distance Handgrip strength 
Subject Group o months 6 12 0 6 12 0 6 
CS Control 24.2 20.9 19.8 240 210 90 16.8 16.7 
SO Control 21.6 16.8 930 1020 59.8 58.9 
VM Control 22.0 19.5 500 360 340 39.8 32.5 
Mean Control 22.6 ± 0.8 19.1 ± 1.2 557 ± 201 530 ± 249 38.8 ± 12.4 36.0 ± 12.3 
lJ Carnitine 17.8 22.0 24.4 190 440 550 25.1 28.3 
Gl Carnitine 21.1 21.8 23.5 630 560 490 40.3 41.0 
KD Carnitine 22.6 21.8 16.2 1020 920 620 60.8 66.3 
DP Carnitine 17.2 16.1 17.2 110 220 230 41.3 56.1 
Mean Carnitine 19.6 ± 1.3 20.4 ± 1.4 20.3 ± 2.1 488 ± 211 535 ± 146 473 ± 85 41.9 ± 7.3 47.9 ± 8.4 
Values (± SEM) are expressed in mmol·{kg dmr1. m. and kg for muscle total carnitine content. walking distance. and handgrip strength. 
respectively. Compared to 0 months. repeat measures at 6 or 12 months demonstrate no statistically significant change. 
12 
14.9 
30.1 
28.6 
43.1 
68.0 
45.2 
46.2 ± 8.1 
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Figure 9. Muscle TC content over the course of the first year of HD treatment in 
ERF patients receiving placebo (white circles) or 10 mg·kg·' i.v. L-camitine (black 
circles) following each HD session. The dashed line represents a patient (KD) 
whose muscle TC store did not appear to respond to i. v. L-camitine treatment. 
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Handgrip strength 
Handgrip strength data are presented in Table 15. There were no 
differences in handgrip strength between the control and carnitine 
patients before the commencement of HD treatment. Furthermore, 
despite handgrip strength appearing to decrease in each control 
patient and increase in each carnitine patient, there were no 
significant differences in handgrip strength over the first year of HD 
treatment and no correlation (r2 = 0.001) between the change in 
muscle carnitine content over the first year of HD treatment and the 
change in handgrip strength. 
Cardiovascular Data 
Baseline transthoracic echocardiograpy demonstrated overall left 
ventricular systolic function to be within normal limits in each subject. 
Left ventricular ejection fraction (LVEF) was > 50%. There were no 
differences between heart rate (HR), mean arterial pressure (MAP) 
and percentage change in stroke volume (SV) from start of dialysis 
between the groups at the first dialysis session. Similarly no 
significant differences were noted between the groups for the same 
variables HR, MAP and SV at 6 and 12 months. (NB only one patient 
remained in the placebo group at 12 months). There were no 
significant changes noted in HR, MAP and stroke volume within the 
first 120 minutes of dialysis in the camitine treated group at time 0 
and 12 months. Cardiovascular data are illustrated in figures 11-13. 
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Heart rate during haemodialysis at 6 months 
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7.5 Discussion 
Skeletal muscle total camitine content is known to be reduced in 
patients undergoing HD treatment, with dialysis vintage being 
strongly correlated to the progression of camitine depletion (170-
172). In the present study, following the first 6 months of HD 
treatment in 3 ERF patients, skeletal muscle TC content declined by 
around 15%, and by a further 5% in 1 of the patients after 12 months 
(Table 15, Fig. 9). This finding is in very good agreement with a study 
in which muscle TC content was reduced by 10 and 20% after the 
first 6 and 12 months, respectively, of HD treatment in·5 ERF patients 
(172). The principal finding of the present study was that intravenous 
administration of 10 mg·kg-1 L-camitine following every HD session 
during the first year of HD treatment in 4 ERF patients was sufficient 
to prevent this observed decline in muscle TC content. A key 
question that has not been addressed in the literature is why and how 
does the muscle TC store become depleted during HD treatment? 
FC is freely filtered into dialysate during HD. In the present study, 
over the first 6 months of HD treatment dialytic TC removal appeared 
to be at a steady-state value of around 1100 IJmol per HD session 
(Fig. 78) and daily urinary TC excretion was on average 100 IJmol 
(Fig. 7 A) in the placebo group, equating to a weekly TC loss of 
approximately 4000 IJmol. Weekly urinary TC excretion has 
previously been calculated in age matched controls to be around 
1700 IJmol (1n). Indeed, weekly urinary TC excretion before the start 
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of HD treatment in both groups of the present study was 
approximately 2000 ~ m o l . . Taken together this equates to a difference 
in TC excretion over 6 months of around 56 mmol between normal 
values and the HD patients in this study. During this period, muscle 
TC content was depleted by around 3 mmol'(kg wet muscler1 (Table 
15). This clearly suggests that the depletion of muscle TC content 
over the first 6 months of HD treatment is at least partly attributable to 
the intradialytic loss of TC during a HD session. Indeed, dialytic TC 
removal and muscle TC depletion within the second 6 months of the 
present study appeared less than in the first 6 months. After the first 
year of HD treatment it would appear that urinary TC excretion is 
negligible (Fig. 7A) (as might be expected due to decreasing urinary 
output) and dialytic camitine removal is approximately 450 ~ m o l l (Fig. 
7B and Fig. 8)_ This equates to a similar, if not lower, weekly TC loss 
compared to age matched controls (1350 vs. 1700 tJmol). This latter 
observation has been reported before (169, 173, 174, 175. 178). It 
would also appear that after the first year of HD treatment, 
intradialytic TC removal remains constant over dialysis vintage (Fig. 
8). Taken together these findings demonstrate. for the first time, that 
the rate of muscle TC depletion that occurs in ERF patients on HD 
treatment is greatest within the first 6-12 months of HD treatment as a 
result of camitine removal during the HD procedure. Indeed, similar to 
the findings of Evans et al (172). muscle TC content was depleted by 
20% following 1 year of HD treatment. In the patients receiving 10 
rng_kg-1 l-camitine (approximately 4500 ~ m o l ) ) following each HD 
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session in the present study, dialytic TC removal was at a steady 
state of 3000 J,lmol per HO session for the first 6 months of treatment 
(Fig. 78), and daily urinary TC excretion averaged around 750 J,lmol 
(Fig. 7A), equating to a weekly TC loss of around 14 mmol. As weekly 
L-camitine administration also equated to approximately 14 mmol for 
the patients in the present study, this would suggest that the loss of 
TC during HO was matched by the administered L-camitine and that 
any excess camitine was removed during HO. This is reflected by the 
finding that muscle TC content remained constant over the first year 
of HO treatment in the camitine group (Table 15, Fig 9). 
Plasma TC concentration before the start of HO treatment in the 
present study was greater than normal (mean of 73.1 ± 9.9 ",mol·L-1 
for both groups; Fig. 6A) and similar to that reported in previous 
studies (27,172). This is probably indicative of an inability to excrete. 
acylcamitine due to impaired renal function. Indeed, in agreement 
with other reports (27), the acyl to free camitine ratio was greater 
than the normal value of 0.2 in both groups. Also in agreement with 
other studies (27,173,174), plasma TC concentration decreased by 
around 40 ~ 0 1 ' L - 1 1 (60 to 80%) per HD session in the control 
patients, and by around 120 ",mol·L-1 (55 to 75%) in the patients 
receiving L-camitine (Fig. 68). 8y dividing the amount of TC removed 
by the dialysate by the fall in plasma TC concentration, the volume of 
distribution for camitine can be calculated as approximately 251. This 
value is slightly higher than that reported in previous studies, which 
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have predicted the volume of distribution for camitine to be equivalent 
to the extracellular space i.e. 20L (201), perhaps suggesting that 
other tissues (e.g. skeletal muscle) may release camitine during the 
HD process. Indeed, it is well reported that the plasma TC 
compartment is replenished within a few hours following a HD 
session (27,173, 174), and muscle TC content has been reported to 
decrease during the dialysis procedure (although the dialysate TC 
content could not explain the 20% decrease in muscle TC content 
after a single HD session;(169, 173». Thus, it could be speculated 
that when the plasma TC concentration falls below a certain threshold 
the 100-fold TC concentration gradient between plasma and muscle 
cannot be maintained via the Na + dependent carnitine transporter 
(OCTN2) and TC is leached from the muscle. L-camitine 
administration probably prevented any loss of TC from skeletal 
muscle (and possibly other tissues) in the present study as post-HD 
plasma TC did not fall below the normal concentration (Fig. 68) 
and/or the timing of the post-HD L-camitine injection prevented the 
need for the characteristic replenishment of the plasma TC pool. 
Another possible explanation is that the HD procedure in itself causes 
muscle damage and, thus, release of muscle TC into the circulation. 
Indeed, uremia per se, rather than disuse, causes atrophy and de-
capillarisation as non-locomotor muscles of HD patients demonstrate 
these characteristics compared to matched controls (187), although 
the mechanism by which this occurs requires further investigation. 
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Exercise tolerance is clearly impaired in ERF patients undergoing HD 
treatment Values for V02peak in HD patients in the literature are 
around 20 ml·min-1·kg-1 and are consistently lower than age-matched 
controls (170, 171, 179). As would be expected with such a chronic 
condition, the aetiology of the impairment in exercise capacity is likely 
multi-factorial and several causes have been suggested. For 
example, muscle strength is reduced in ERF patients undergoing HD. 
This is most probably due to the muscle atrophy that occurs in HD 
patients and is an accurate predictor of aerobic exercise capacity 
( V ~ p e a k , , exercise duration, peak ventilation, and peak blood lactate 
concentration), suggesting that altered skeletal muscle function could 
partly explain the impaired exercise tolerance of HD patients (179). In 
addition, skeletal muscle blood flow is greatly reduced in response to 
exercise in HD patients. There are necrotic capillaries within the 
muscle microcirculation, and there are fewer capillaries per muscle 
fibre compared to age-matched sedentary controls (179-181). This 
would suggest that oxygen delivery to skeletal muscle during exercise 
limits aerobic capacity. Indeed, impaired 02 transfer from the muscle 
microcirculation to mitochondria has been demonstrated during 
exercise in HD patients compared to age-matched sedentary controls 
(183,184). However, although exercise training has been reported to 
increase maximal workload, muscle capillarisation and muscle fibre 
cross-sectional area, and reduce the number of atrophic fibres (170, 
187,202), there are conflicting reports as to whether exercise training 
increases V02m8X (27,170,187,202,203). Furthermore, increasing 
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haemoglobin to a normal content in anaemic HD patients using 
recombinant human erythropoietin therapy appears to have little or no 
effect on aerobic exercise capacity (183,186,204). On the other hand, 
abnormal skeletal muscle energy metabolism could playa role in the 
impaired aerobic capacity observed in these patients. For example, at 
the same relative exercise intensity it has been demonstrated that HD 
patients have a lower intracellular pH and greater phosphocreatine 
(Per) degradation (measured by magnetic resonance spectroscopy) 
compared to age-matched sedentary controls (185,186), and the 
lactate threshold is reached at a much lower workload (171). The fact 
that this increased anaerobic glycolysis occurs early in exercise (185) 
would suggest an intrinsic impairment in mitochondrial ATP 
production during exercise. However, it has been consistently 
demonstrated that mitochondrial capacity (electron transport chain 
activity) appears normal, if not increased, in isolated muscle 
mitochondria from HD patients, possibly via an adaptive mechanism 
(180, 187,203,205,206), and muscle mitochondrial content appears 
normal (206). Therefore, if skeletal muscle energy metabolism were 
limiting to aerobic exercise capacity in HD patients, it is likely that an 
enzyme inhibition or substrate deficiency per se would be involved. In 
addition, the finding that some HD patients do not respond to 
exercise training at all, whereas renal transplant patients do (207), 
would suggest that the HD procedure itself impacts on the impaired 
exercise tolerance. 
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In this respect, the progressive depletion of skeletal muscle camitine 
content in HD patients has been correlated with exercise capacity 
(171). Individuals with primary/systemic carnitine deficiency, an 
autosomal recessive disorder of fatty acid oxidation caused by 
mutations in the gene encoding OCTN2, have been reported to have 
a muscle TC content of less than 10% of normal, which is associated 
with pronounced exercise intolerance and muscle weakness (208-
210). Haemodialysis patients also have greatly reduced muscle CPT1 
activity compared to control (170). Furthermore, both oral and 
intravenous L-camitine supplementation in ERF patients undergoing 
long-term HD treatment have been reported to increase aerobic 
exercise capacity (29,188 190, 211), muscle cross sectional area 
(29), muscle fibre diameter (30,191,192), and muscle strength (29). In 
contrast, previous studies have also failed to show any significant 
effect of intravenous L-camitine administration on muscle anaerobic 
ATP production (measured by magnetic resonance spectroscopy) in 
HD patients during exercise (212). However, whether the 
maintenance of skeletal muscle TC content observed in the present 
study with L-camitine treatment (Table 15, Fig. 8) was associated 
with a prevention of the decline in aerobic capacity and muscle 
function associated with HD treatment is unclear, mainly because we 
were unable to detect an effect of HD treatment on aerobic capacity 
in the control group (Table 15). This could be due to the small 
number of patients, or because muscle TC was not depleted to a 
content that was limiting to aerobic capacity. Nevertheless, aerobic 
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capacity and muscle strength appeared to be maintained in the 
camitine group (Table 15) and there was a weak correlation (P=0.06; 
Fig. 10) between the change in muscle TC content after 12 months of 
HD treatment and the change in aerobic capacity (total walking 
distance during the incremental exercise test). 
Cardiac complications are the leading cause of mortality in patients 
with chronic renal failure. It has been widely established that patients 
with ERF undergoing haemodialysis therapy exhibit low endogenous 
levels of L-Camitine and elevated acylcamitine levels. The clinical 
implications of this altered camitine profile are not entirely clear. 
Numerous studies over the past few decades have investigated the 
effects of L-camitine on cardiac dysfunction and intradialytic 
complications thereof, notably intradialytic hypotension. 
Administration of L-camitine has been shown to be associated with a 
significant reduction in the number of intradialytic hypotensive events 
when compared with placebo (29, 30). A Significant correlation 
between L VEF and endogenous L-camitine levels has been reported. 
These patients exhibiting considerable improvement in L VEF after 
administration of L-camitine post dialysis for a period of three months 
(213). This was particularly pronounced in patients experiencing 
recurrent hypotensive episodes. These symptomatic patients had a 
significantly lower ejection fraction than their asymptomatic 
counterparts. Further studies have provided similar findings (28). In 
the present study baseline echocardiography revealed normal left 
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ventricular function in all patients. Left ventricular ejection fraction 
was >50%. Finometer data did not demonstrate any significant 
differences in intradialytic MAP, HR and SV between patients treated 
with L-camitine or placebo over the study period. There was also no 
Significant difference between values observed within the carnitine 
group at baseline and at 12 months. Interestingly within this small 
study no patients demonstrated problems with episodes of significant 
intradialytic hypotension. This is slightly unusual and would suggest 
that our particular study group is not typical of the larger 
haemodialysis population. Fagher et al.(214), conducted a 6 week, 
double blind, controlled study in 28 haemodialysis patients, who 
received 2g N L-camitine after each haemodialysis session. This 
demonstrated no effect of L-camitine on left ventricular function. The 
average value of ejection fraction was 62% at baseline however. 
This might imply that the greatest benefit from camitine replacement 
is expected only in patients whose baseline cardiac function is 
significantly abnormal. 
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CONCLUSIONS, LIMITATIONS & FUTURE WORK 
Chronic kidney disease is associated with profound alterations in 
body composition that have far reaching consequences at cellular 
and systemic level in addition to overall patient function. Therapeutic 
manoeuvres in the predialysis population to preserve eGFR may lead 
to an augmentation in functional anomalies. A similar paradigm exists 
within the dialysis population where interventions directed towards 
maintenance of adequate homeostasis including the dialysis process 
itself may actually adversely effect function at all levels. 
Goal directed antihypertensive treatment in older CKD subjects 
We have demonstrated that in a carefully selected group of 
individuals it is possible to achieve target blood pressure within older 
subjects with CKD and demonstrated stability in renal function at 12 
months. Using the Timed get-Up and Go test as a measure of 
function we have demonstrated a significant decline within the CKD 
subjects which was not reflected in the non-CKD group. However, 
based on classification of the TUG testing system this decline only 
relates to minimal impairment. This was not associated with an 
increased risk of falls in this patient group. In fact the falls rate within 
groups (CKD, non-CKD) or taking the study group as a whole, was 
less than would be expected in the general population within the age 
range included in this study. 
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There were no significant differences in BIA measurements of 
muscle, bone or fat mass in the short-term (4 weeks) resulting from 
antihypertensive therapy. At twelve month follow up eKD subjects 
demonstrated a higher mean decline in muscle mass than non-CKD 
subjects although this difference did not reach statistical Significance. 
This increased decline might be expected due to uraemic effects on 
muscle. 
There were no significant changes in fat mass over time. BIA 
measured bone mass declined in both groups over the study period 
but this was not significantly different between groups. Based on the 
results from this study we therefore conclude that antihypertensive 
therapy does not result in significant alterations in muscle, bone or fat 
mass above any change that might be expected in a non-CKD 
population. 
The major limitation with this study relates to selection bias. We have 
excluded subjects with background morbidities that might predispose 
to functional abnormalities and falls such as diabetes mellitus (eg. 
autonomic neuropathy, peripheral neuropathy) and those subjects 
already attending falls services. Indeed the greatest risk factor for 
falls is the presence of previous falls. However, with this particular 
study we have demonstrated that with careful individualised treatment 
goal directed antihypertensive therapy is safe and an effective 
intervention to preserve renal stability in subjects with CKD. 
To take this work forward in the Mure it would be useful to involve 
subjects with greater degree of renal impairment. Mean eGFR in the 
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CKD group was only 40mlslmin. Effects of features associated with 
uraemia such as inflammation and acidosis, which we have not really 
considered independently in this study are more likely to be of greater 
significance in subjects with higher levels of renal impairment. 
Bone collagen formation rates and expression of osteotropic 
factors 
There is an increasing evidence base demonstrating that far from 
being an inert structural support system the skeleton has major 
dynamic functions that are essential for normal homeostasis. There 
are clear links between skeletal dysfunction and predisposition to 
fracture potential, bone pain and importantly the development of 
vascular calcification which may also be impacted upon by our 
attempts to 'normalise' surrogate markers of bone turnover and 
provide sufficient activity to buffer the internal milieu. 
Our study in male chronic haemodialysis patients is the first to 
compare iPTH measurement with a measure of dynamic bone 
turnover. In the 9 patients studied iPTH did not correlate with bone 
collagen FSR. Bone collagen FSR was higher than matched non-
CKD controls. The significance of these findings is however severely 
impaired by the small numbers studied. Unfortunately due to 
unanticipated problems with methodology we were unable to assess 
the effect of serum phosphate optimisation on bone collagen FSR 
and any differential effect of calcium versus non-calcium containing 
phosphate binder medication. The reliance on a baseline skin sample 
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as a surrogate marker of bone turnover revealed unanticipated 
problems. In non-CKO subjects previous work using this specific 
technique had shown that collagen kinetics within skin were 
comparable to bone. Unfortunately we observed that levels of 15N 
within skin at baseline were far in excess of those post 15N labelled 
proline found in bone and therefore it was not possible to estimate 
uptake. The reasons for this are unclear. Further studies using 
alternate markers or investigation of uraemic effects on skin collagen 
are required before this technique can be applied in this setting again 
but the concept of measuring dynamic bone function over a period of 
hours involving single bone biopsy would be very appealing to 
improve in our understanding of the effects of uraemia and its 
consequent treatment on overall bone function. The relative acellular 
nature of bone, small samples obtained in this study and instability of 
RNA made observation of expression of gene products of bone 
turnover difficult. Larger samples would help with this problem but 
increase the potential risks of bone biopsy. Recent development of 
newer preservatives to prevent the denaturing of RNA might prevent 
this problem. 
The interplay of effects of uraemia on the skeleton is complex. Given 
the invasive nature of bone biopsy the search for adequate 
serological and urinary markers to demonstrate skeletal activity is 
extremely important. To date assessment of bone health remains 
reliant on multiple factors. 
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Myocardial contractile function and intradla/ystic hypotension 
Intradialystic hypotension remains highly prevalent in the chronic 
haemodialysis population, the resulting myocardial hypo perfusion , 
segmental ischaemia and subsequent myocardial dysfunction 
(myocardial stunning) lead to irreversible left ventricular dysfunction. 
We have demonstrated that in a group of chronic haemodialysis 
patients Oobutamine atropine stress with simultaneous non-invasive 
measurement of cardiac .parameters can be performed without 
untoward side effects and used to differentiate correctly between 
those known to be hypotension prone and those who are not. Failure 
to increase cardiac output was primarily due to a greater fall in stroke 
volume in the hypotension prone group as both groups were able to 
increase their heart rate by similar amounts. 
This study is again limited by a small number of subjects involved and 
should be repeated with greater numbers. In the future this technique 
could be applied to a clinical setting in order to identify patients with 
low myocardial functional reserve, without exposing them to recurrent 
episodes of dialysis induced hypotension and resultant permanent 
myocardial injury, with earlier utilisation of tess haemodynamically 
stressful dialysis treatments. 
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Camitine depletion and skeletal and myocardial functional 
effects of camitine replacement in incident chronic 
haemodia/ysis patients 
The characteristics of cardiovascular disease and progressive 
impairment of exercise capacity have been linked to reductions in 
serum L-camitine levels and skeletal muscle carnitine. Major camitine 
stores are within skeletal muscle and cardiac muscle where its main 
role is in the translocation of fatty acids into mitochondria for 13-
oxidation and eventually ATP production. During dialysis camitine is 
readily filtered and not replaced. Plasma camitine levels are 
subsequently replenished by skeletal and possibly myocardial stores. 
We have demonstrated that the characteristic decline of muscle TC 
content observed in ERF patients is greatest within the first 6-12 
months of HD treatment and is associated with a substantial 
intradialytic removal of TC. The reason for the greater loss of TC from 
the muscle store into the dialysate during the first year of HD is not 
known and warrants further investigation. It is unclear from the 
present study whether it results in impaired aerobic capacity on 
muscle function. After the first year of HD treatment, factors other 
than dialytic TC loss, such as a decrease in dietary camitine intake 
and/or decrease in endogenous synthesis (particularly in the failing 
kidney) most likely contribute to the progressive depletion of the 
muscle TC store. This also requires further investigation. Another 
important finding from the present study was that intravenous 
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administration of 10 mg·kg-1 L-carnitine following every HD session 
(i.e. 3 times per week) is more than sufficient to prevent the decline in 
muscle camitine content over the first year of HD treatment, and also 
appears to maintain exercise tolerance. In the context of muscle TC 
content, the guideline from the National Kidney Foundation of 
America recommending the intravenous administration of 20 mg·kg-1 
L-camitine three times a week for 9 to 12 months (198) was 
excessively high. 
Regarding cardiovascular function, the present study does not 
demonstrate any measurable benefit. The study is severely impaired 
by a very small number of participants. This is similar to many other 
previous studies. Further larger scale investigation, with more 
standardised dose of camitine and assessment methods of 
cardiovascular function are required. 
Summary statement 
The effects of uraemia on body composition and function are 
innumerable. Although commonly utilised therapeutic interventions 
within the CKD population aim to ameliorate some of the 
abnormalities found our increasing knowledge base serves to 
illustrate deleterious effects of these treatments and how much more 
we have to learn. This thesis merely scratches the surface of the 
problem and much more work is required to begin to comprehend the 
consequences of the failing kidney and the modifications we can 
make to produce the best outcome for our patients. 
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ACEi Angiotensin converting enzyme 
inhibitors 
acylCoA Acyl Coenzyme A 
AHT Antihypertensive therapy 
APKD Adult Polycystic kidney disease 
ARB Angiotension II receptor antagonists 
BIA Bioelectrical impedance analysiS 
BMI Body Mass Index 
BP Blood pressure 
BRS Baroreflex sensitivity 
BSU Bone Structural Units 
CAPO Continuous Ambulatory Peritoneal 
Dialysis 
cCalcium corrected calcium 
CFR Collagen formation rate 
CKD-MBD Chronic Kidney Disease-Mineral 
Bone Disorder 
Cm Centimetre 
CO Cardiac Output 
CPT1 Camitine palmitoyltransferase 1 
CrCl Creatinine clearance 
CRP C-reactive protein 
CSA Cross sectional area 
CSR Collagen SyntheSiS Rate 
Ct Cycle threshold 
CT Computed tomography 
CTA Clinical Trial Approval 
CTx C-telopeptide 
CVD Cardiovascular Disease 
DAS Dobutamine-atropine stress 
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DBP Diastolic Blood Pressure 
DEXA Dual Energy Xray Absorptiometry 
ON Diabetic nephropathy 
DNA Dioxyribonucleic acid 
ECF Extra cellular fluid 
ECW Extra cellular water 
EDTA Ethylenediaminetetraacetic acid 
eGFR estimated Glomerular Filtration Rate 
ERF Established Renal Failure 
FBC Full Blood count 
FC Free Camitine 
FGF23 Fibroblast growth factor 23 
FSR Fractional Synthetic Rate 
g grams 
GC-C-IRMS Gas chromatography-combustion-
isotope ratio mass spectrometry 
GC-MS Gas Chromatographic-Mass 
Spectrometric (analysis) 
GFR Glomerular Filtration Rate 
GI Gastrointestinal 
GN Glomerulonephritits 
GP General Practitioner 
HD Haemodialysis 
HP HypotenSion Prone 
HR Hypotension Resistant 
IDH Intradialytic Hypotension 
IGFI Insulin like growth fador I 
IHD Ischemic Heart Disease 
Il-6 Interleukin-6 
iPTH intactPTH 
Kg Kilogram 
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K/DOQI Kidney Disease Outcomes Quality 
Initaitive 
L Litres 
LVEF Left Ventricular Ejection Fraction 
LVH Left Ventricular Hypertrophy 
LVMI Left Ventricular Mass Index 
M Molar 
m2 metres squared 
MAP Mean Arterial Pressure 
MDRD Modification of diet in renal disease 
MHRA Medicines and Healthcare products 
Regulatory Agency 
MIA Malnutrition-Inflammation-
Atherosclerosis complex 
min minute 
ml millilitres 
mmHg millimetres of mercury 
mRNA Messenger RNA 
NaCI Sodium Chloride 
NAP N-acetyl-n-propyl esters 
NHS National Health Service 
ns Not significant 
NTx N-telopeptide 
NYHA New York Heart Association 
OCTN2 Na dependent carnitine transporter 
OFC Osteitis Fibrosa Cystica 
OPG Osteoprotegerin 
PCR Polymerase Chain Reaction 
PTH Parathyroid Hormone 
RANKL Receptor activator NFkB ligand 
RNA Ribonucleic Acid 
RT-PCR Reverse transcriptase polymerase 
chain reaction 
s Seconds 
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SBP Systolic Blood Pressure 
SV Stroke Volume 
TBW Total Body Water 
TC Total Camitine 
TNF-a Tumour necrosis factor- a 
TPR Total peripheral resistance 
TUG Timed get-Up and Go 
U&E Urea & Electrolytes 
uPCR urine Protein:Creatinie ratio 
V02 Peak Values for peak oxygen uptake 
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